


Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles, processes for preparing them and compositions containing them

Background of the Invention

In U.S. Pat. No. 3,936,470 and Belg. Pat. No. 837,831 there are described a number of 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles and 1H-1,2,4-triazoles having antifungal and antibacterial properties. The compounds of this invention differ from the foregoing essentially by the substitution of the aryloxy-moiety with a 4-phenylpiperazinyl group, wherein said phenyl is further substituted with a heterocyclic radical which is attached to the phenyl group by a carbon-nitrogen bond. Similar compounds wherein a heterocyclic radical is attached directly to the aryloxy group by a carbon-nitrogen bond are described in DE-A-2 803 870.

Description of the preferred embodiments


This invention is concerned with novel 1H-imidazole and 1H-1,2,4-triazole derivatives which may structurally be represented by the formula:



and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein:


Q is a member selected from the group consisting of CH and N;

Ar is a member selected from the group consisting of phenyl, thienyl, halothienyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl; and the radical Y is a member selected from the group consisting of a 1H-pyrrol-1-yl radical of the formula




wherein R¹, R², R³ and R⁴ are each independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-lower alkyl;

a 1H-pyrazol-1-yl radical of the formula




wherein R⁵, R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-lower alkyl;

a 1H-imidazol-1-yl radical of the formula



wherein R⁸ is selected from the group consisting of hydrogen, lower alkyl, mercapto, lower alkylthio and aryl-lower alkylthio, and R⁹ and R¹⁰ are each independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-lower alkyl;
a 1H-1,2,4-triazol-1-yl radical of the formula

5




10

(d)

wherein either of R¹¹ and R¹² is selected from the group consisting of hydrogen, hydroxy, mercapto, lower alkylthio and aryl-lower alkylthio, the remaining being selected from the group consisting of hydrogen, lower alkyl and aryl-lower alkyl;
a 4H-1,2,4-triazol-4-yl radical of the formula

15



20


(e)

25

wherein R¹³ is selected from the group consisting of hydrogen, mercapto, hydroxy, lower alkylthio and aryl lower alkylthio, and R¹⁴ is selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-lower alkyl;

a 2,3-dihydro-4H-1,2,4-triazol-4-yl radical of the formula

30




35

(f)

wherein R¹⁵ is selected from the group consisting of lower alkyl and aryl-lower alkyl and R¹⁶ is selected from the group consisting of hydrogen, lower alkyl, and aryl-lower alkyl;
a 1H-1,2,3,4-tetrazol-1-yl radical of the formula

40



45

(g)

wherein R¹⁷ is selected from the group consisting of hydrogen, mercapto, lower alkyl, aryl and aryl-lower alkyl;

50

wherein said aryl as used in the foregoing definitions is selected from the group consisting of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl.

55

It is understood that radicals of formulas (c) and (g) wherein R⁸, respectively R¹⁷, stand for mercapto, as well as radicals of formulas (d) and (e) wherein R¹¹ or R¹², respectively R¹³, stand for mercapto or hydroxy, may also exist in their tautomeric thioxo, respectively oxo, forms. Such thioxo and oxo forms, although not explicitly indicated in the above structures, are naturally intended to be within the scope of formula (i).


60

The preferred compounds of this invention are those where the 4-phenylpiperazinyl function is attached to the phenoxyethyl moiety in the para position.


As used in the foregoing and in following definitions the term "halo" is generic to fluoro, chloro, bromo and iodo; and "lower alkyl" means straight and branched hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, 1-methylpropyl, 2-methylpropyl, butyl, pentyl, hexyl and the like.

65

In order to simplify the structural representation of the compounds (I) and of certain starting materials and intermediates used in the preparation thereof, the 2-Ar-2-(1H-imidazol-1-ylmethyl or 1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl group, wherein Ar is as previously defined, will hereinafter be represented by the symbol D:




The compounds of formula (I) wherein Y is as previously defined, but other than a radical of formula (c) or (g) wherein R⁸, respectively R¹⁷, is mercapto and other than a radical of formula (d) or (e) wherein R¹¹ or R¹², respectively R¹³, is mercapto or hydroxy, said Y being represented by Y' and said compounds being represented by the formula (I'), can be prepared by O-alkylating an appropriate phenol of formula (III) with a reactive ester of formula (II).



In formula (III), W has the meaning of a reactive ester residue such as, for example, halo, preferably chloro, bromo or iodo, or a sulfonyloxy group such as, for example, methylsulfonyloxy or 4-methylphenylsulfonyloxy and the like.


The reaction of (II) with (III) is carried out under art-known conditions of performing O-alkylations with reactive esters. The reaction is generally carried out in an appropriate reaction-inert organic solvent such as, for example, N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphorotriamide, dimethylsulfoxide, 4-methyl-2-pentanone and the like, optionally in admixture with other reaction-inert solvents such as, for example, aromatic hydrocarbons, e.g., benzene, methylbenzene, dimethylbenzene and the like. Further it is advantageous to add to the reaction mixture an appropriate base such as, for example, an alkali metal hydride or carbonate, in order to enhance the rate of the reaction. Otherwise it may be advantageous to first convert the substituted phenol (III) into a metal salt thereof, preferably the sodium salt, in the usual manner, e.g., by the reaction of (III) with metal bases such as sodium hydride, sodium hydroxide and the like, and to use thereafter said metal salt in the reaction with (II). Somewhat elevated temperatures are appropriate to enhance the reaction rate and most preferably the reaction is carried out at from 80°C to 130°C.

The compounds of formula (I), wherein Y is as previously defined, can generally be prepared by cyclizing an intermediate of formula (IV) with an appropriately substituted aminobenzene of formula (V).




The reaction is carried out by stirring the reactants together in the presence of an appropriate polar solvent, e.g., water, in admixture with an appropriate water-miscible organic solvent such as, for example, 2-propanol, 2-propanone and the like, preferably at an elevated temperature, in order to enhance the rate of the reaction, and, most preferably, in the presence of an appropriate alkali- or earth alkali metal iodide such as, for example, potassium iodide.

The compounds of formula (I) can alternatively be prepared by N-alkylating a compound of formula (VI) with an appropriately substituted halo-benzene of formula (VII), following standard N-alkylating procedures.




Said N-alkylation may be carried out in the usual manner, e.g. by stirring the reactants together, preferably at somewhat elevated temperatures in an appropriate organic solvent such as, for example, dimethylsulfoxide, dimethylformamide and the like, in the presence of an appropriate base such as, for example, an alkali metal hydride or carbonate.


Still another method of preparing the compounds of formula (I) is by cyclizing an appropriate intermediate of formula (VIII), wherein A is an amino group of a suitable derivative thereof, with an appropriate cyclizing agent, following art-known procedures, and, if desired, introducing substituents into the thus obtained heterocyclic compounds.



The nature of A in formula (VIII), as well as the nature of the cyclizing agent to be used in the cyclization step, depend upon the meaning of Y in the desired compounds (I) as will be explained hereafter in more detail.

The compounds of formula (I) wherein Y stands for the radical (a), wherein R¹, R², R³ and R⁴ have the previously defined meaning, said compounds being represented by the formula (I-a), can be derived from an appropriate amine of formula (VIII-a), by cyclizing the latter with an appropriate dione of formula (IX-a) or a tetrahydro-2,5-di-(lower alkoxy)furan of formula (IX-b).






The reaction of (VIII-a) with (IX-a) is conveniently carried out by stirring and refluxing the reactants together in an appropriate solvent, e.g., a lower alkanol such as ethanol and the like, preferably, but not necessarily, in the presence of an appropriate base such as, for example, an alkali metal carbonate, e.g., potassium carbonate and the like.

The reaction of (VIII-a) with (IX-b) is preferably carried out in a polar solvent, e.g., acetic acid and the like.


The compounds of formula (VIII-a), used as intermediates herein, display strong antifungal and antibacterial properties themselves and both as useful intermediates herein and as antifungal and antibacterial substances they constitute an additional feature of this invention.

The compounds of formula (I) wherein Y stands for the radical (b), wherein R^5 , R^6 and R^7 have the previously defined meaning, said compounds being represented by the formula (I-b), can be derived from an appropriate hydrazine of the formula (VIII-b), which is usually employed in the form of an acid addition salt, by cyclizing the latter with an appropriate dione of formula (X).






The reaction of (VIII-b) with (X) is carried out following the same procedure as for the preparation of (I-a) starting from (VIII-a) and (IX-a). When R^5 is hydrogen, the adjacent carbonyl group of (X) is preferably acetalized prior to reacting said (X) with (VIII-b) in order to obtain a pyrazole derivative wherein R^6 is unambiguously located at the 5-position. Mixtures of position isomers which can otherwise be obtained when using unacetalized aldehydes or ketones of formula (X) may be subjected to standard isolation and purification procedures to separate the pure constituents from each other.

The compounds of formula (I) wherein Y stands for a radical (c) wherein R^9 and R^{10} are as previously defined and wherein R^8 stands for mercapto, said compounds being represented by the formula (I-c-1), can be prepared by cyclizing an appropriate isothiocyanate of formula (VIII-c) with an appropriate amino-ethanone or amino-acetaldehyde of formula (XI).




The foregoing reactions are schematically illustrated as follows:





The intermediates of formula (VIII-d-1), used as starting materials herein, may be prepared by the reaction of an alkali metal isothiocyanate, e.g., potassium isothiocyanate, with the corresponding hydrazine derivative of formula (VIII-b).

Still another method of preparing the compounds of formula (I-d-1) is by reacting a hydrazine hydrochloride of formula (VIII-b) with a compound of formula (XIII-d) wherein X is O or S, in N,N-diethylethanamine, washing the reaction mixture with water, evaporating off the solvent and thereafter stirring and heating the residue in a mixture of dichloromethane and ethanol in the presence of alkali.




The compounds of formula (I) wherein Y stands for the radical (d) wherein R¹² is R¹², and wherein R¹¹ is hydrogen, said compounds being represented by the formula (I-d-2), can easily be prepared by desulfurating a corresponding compound of formula (I-d-1), wherein XH is SH, said compounds being represented by the formula (I-d-1-a) following the same procedure as for the desulfuration of (I-c-1) to prepare (I-c-2).

The compounds of formula (I) wherein Y stands for the radical (d) wherein R¹² is R¹², and wherein R¹¹ is lower alkylthio or aryl-lower alkylthio, said compounds being represented by the formula (I-d-3), can be obtained by S-alkylating a compound of formula (I-d-1-a) with a reactive ester of formula (XV-a), wherein W has the previously defined meaning and wherein R¹¹ stands for lower alkyl or aryl-lower alkyl, following the same procedure as for the preparation of (I-c-3) starting from (I-c-1) and (XII).


Following the same desulfurating procedure as described hereinabove, the compounds of formula (I-d-3) may be converted into the compounds of formula (I-d-2).

The foregoing reactions are schematically illustrated as follows:



The compounds of formula (I) wherein R¹² is XH, X being O or S, and wherein R¹¹ is hydrogen, lower alkyl or aryl-lower alkyl, said R¹¹ being represented by R¹¹_b and said compounds by the formula (I-d-4), may be prepared by cyclizing an appropriate (aminocarbonyl)- or (aminothiocarbonyl)hydrazine of formula (VIII-d-2) with an appropriate carboxylic acid (XIII-d) or a functional derivative thereof, e.g., an acyl halide, an ester or, preferably, an imidamide.

Said reaction is preferably carried out in the presence of an appropriate organic solvent, e.g., a lower alkanol such as, for example, 2-propanol, butanol and the like.




The compounds of formula (I) wherein Y represents the radical (d) wherein R^{12} is hydrogen and wherein R^{11} has the meaning of R^{11}_b , said compounds being represented by the formula (I-d-5), may be prepared by desulfurating a compound of formula (I-d-4) wherein X is S, (I-d-4-a), e.g., by treating the latter with Raney-nickel or with diluted nitric acid.


The compounds of formula (I) wherein Y represents the radical (d) wherein R^{12} is lower alkylthio or aryl-lower alkylthio and wherein R^{11} has the meaning of R^{11}_b , said compounds being represented by the formula (I-d-6), may be prepared by S-alkylating a compound of formula (I-d-4-a) with a reactive ester of formula (XV-b), wherein W is as previously described and wherein R^{12}_b is lower alkyl or aryl-lower alkyl, following the previously described procedure for the preparation of (I-c-3) starting from (I-c-1) and (XII).

Following the desulfurating procedure described hereinabove, the compounds of formula (I-d-6) may in turn be converted into the compounds of formula (I-d-5).

The foregoing reactions are schematically illustrated as follows:



The compounds of formula (I) wherein Y stands for a radical of formula (e) wherein R^{14} has the previously defined meaning and wherein R^{13} stands for mercapto or hydroxy, said R^{13} being represented by XH, wherein X is O or S and said compounds by the formula (I-e-1), can be derived from an intermediate of formula (VIII-e) by cyclizing the latter with an appropriate imidamide of formula (XVI) or an acid addition salt thereof.




25 The compounds of formula (I) wherein Y stands for the radical (e) wherein R¹⁴ is as previously defined and wherein R¹³ stands for lower alkylthio or aryl-lower alkylthio, said R¹³ being represented by SR^{13a}, wherein R^{13a} is lower alkyl or aryl-lower alkyl, said compounds being represented by the formula (I-e-3), can be prepared by S-alkylating a compound of formula (I-e-1) wherein R¹³ is —SH, (I-e-1-a), with a reactive ester of formula (XVII), wherein W has the previously defined meaning, following art-
30 known procedures.

35 The foregoing reactions are schematically illustrated as follows:





The compounds of formula (I) wherein Y represents a radical (f) wherein R^{15} and R^{16} have the previously defined meaning, said compounds being represented by the formula (I-f), can be derived from an appropriate compound of formula (I-e-1), wherein XH stands for OH, (I-e-1-b), by N-alkylating the latter with an appropriate reactive ester of formula (XVIII), wherein W and R^{15} have the previously defined meanings.





Said N-alkylation may be carried out in the usual manner, e.g., by stirring and heating the reactants together in an appropriate organic solvent such as, for example, dimethylsulfoxide and the like, in the presence of an appropriate base such as, for example, an alkali metal hydride or carbonate.

The compounds of formula (I) wherein Y stands for the radical (g) wherein R^{17} is as previously defined, but other than mercapto, said compounds being represented by the formula (I-g-1) and said R^{17} by R^{17}_a , can generally be derived from an intermediate of formula (VIII-a) by cyclizing the latter with an azide, preferably an alkali metal azide, e.g., sodium azide, and an appropriate 1,1',1''-tri(lower alkoxy)-alkane of formula (XIX) in an appropriate acidic medium, e.g., acetic acid, preferably under heating.




The compounds of formula (I), wherein Y stands for the radical (g) wherein R^{17} stands for mercapto, said compounds being represented by the formula (I-g-2) can be obtained by cyclizing an isothiocyanate of formula (VIII-c) with an appropriate azide, preferably sodium azide, in an appropriate organic solvent, e.g., a lower alkanol such as methanol, ethanol, 2-propanol and the like, in the presence of alkali.



Said cyclization reaction may also be carried out by stirring (VIII-c) with an azide in the presence of an appropriate quaternary ammonium salt, preferably N,N,N-triethylbenzenemethanaminium chloride, in a suitable solvent system such as, for example, water, preferably in admixture with an appropriate organic solvent such as, for example, 1,4-dioxane, to better solubilize the reactants.


The compounds of formula (I-g) wherein R¹⁷ is hydrogen, (I-g-3), may be prepared by desulfurating a compound of formula (I-g-2) following art known procedures.




The imidazole- and triazole-derivatives of formula (I), obtained in base form in the foregoing preparations, may be converted to their therapeutically useful acid addition salts by reaction with an appropriate acid, as, for example, an inorganic acid such as hydrohalic acid, i.e., hydrochloric, hydrobromic or hydroiodic acid; sulfuric, nitric or thiocyanic acid; a phosphoric acid; an organic acid such as acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, 1,4-butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxy-1,4-butanedioic, 2,3-dihydroxy-1,4-butanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, benzoic, 3-phenyl-2-propenoic, α -hydroxybenzeneacetic, methanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, 4-methylbenzenesulfonic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic, 2-phenoxybenzoic or 2-acetyloxybenzoic acid. The salts are in turn converted to the corresponding free bases in the usual manner, e.g., by reaction with alkali such as sodium or potassium hydroxide.

A number of the intermediates and starting materials used in the foregoing preparations are known compounds, others may be prepared according to art-known methodologies of preparing similar compounds and some of them are novel and consequently their preparation will be described hereafter.

The intermediates of formula (III), wherein Y' has the previously defined meaning, can generally be prepared from the corresponding methoxy-substituted compounds of formula (XX) by converting the methoxy group of the latter into a hydroxy group by acid hydrolysis using a strong non-oxidizing mineral acid such as, for example, hydrobromic acid in glacial acetic acid.




The intermediates of formula (XX), used as starting materials herein, can be obtained by cyclizing a N,N-bis(2-haloethyl)-4-methoxybenzenamine of formula (XXI), with an appropriate benzenamine of formula (XXII), wherein Y' has the previously defined meaning, following the same procedure as described for the preparation of (I) starting from (IV) and (V).




The preparation of the compounds of formula (XXI) is described in J. Chem. Soc., 1949, 183-191.

The intermediates of formula (XX) can alternatively be prepared by cyclizing an appropriate intermediate of formula (XXIII), wherein A is an amine group or a derivative thereof, with an appropriate cyclizing agent and, if desired, introducing appropriate substituents into the thus obtained heterocyclic


compounds, following the previously described methods for the preparation of compounds (I) starting from (VIII).




10 The intermediates of formula (XXIII) wherein A stands for an amino group, (XXIII-a), can be prepared by N-alkylating a compound of formula (XXIV) with an appropriate chloro-nitrobenzene (XXV), following standard N-alkylating procedures, and subsequently reducing the thus obtained nitro-compound (XXVI), e.g., by catalytic hydrogenation in a relatively polar solvent, such as, for example, methanol, in the presence of an appropriate catalyst, e.g., palladium on charcoal.




40 The intermediates of formula (XXIII), wherein A represents an isothiocyanate group, (XXIII-b), can be derived from an appropriate compound of formula (XXIII-a), by treating the latter with carbon disulfide in the presence of dicyclohexylcarbodiimide, preferably in the presence of an appropriate organic solvent such as, for example, pyridine.




55 The intermediates of formula (XXIII), wherein A stands for a hydrazinecarbothioamide group, (XXIII-c-1), can be derived from a compound of formula (XXIII-b), by stirring and heating the latter with hydrazine hydrate in the presence of an appropriate solvent such as, for example, 1,4-dioxane and the like.




The intermediates of formula (XXIII), wherein A stands for a hydrazinecarbonamide group, (XXIII-c-2), can be derived from a compound of formula (XXIII-a), by stirring and heating the latter with phenylcarbonohalogenide in an appropriate solvent, e.g., dichloromethane, in the presence of an appropriate base such as, for example, pyridine and the like, and subsequently reacting the thus obtained (XXIII-d) with hydrazine hydrate in the presence of an appropriate solvent, e.g., 1,4-dioxane and the like.



The intermediates of formula (IV) can be prepared by O-alkylating a 4-amino-phenol of formula (XXVI) with a reactive ester of formula (II), following the same procedure as previously described herein for the preparation of (I'), and subsequently reacting the thus obtained compounds of formula (XXVII) with an appropriate dihaloethane, following the method described in J. Chem. Soc., 1949, 183-191.




The intermediates of formula (V) and the starting materials of formula (XXII) can generally be prepared by reducing a corresponding nitro compound of formula (XXVIII), respectively (XXVIII-a) e.g., by catalytic hydrogenation in a relatively polar solvent such as, for example, an alcohol, in the presence of an appropriate catalyst, e.g., platinum on charcoal.



The starting materials of formula (XXVIII), respectively (XXVIII-a), can be prepared starting from

appropriate precursors, following art-known procedures as previously described herein for the preparation of compounds of formula (I) starting from (VIII) and an appropriate cyclizing agent.

The intermediates of formula (VI) can be obtained by O-alkylating an appropriate compound of formula (XXIX) with a reactive ester of formula (II), following standard O-alkylation procedures.




Starting materials of formula (II) wherein Q stands for CH and methods of preparing the same are described in Belg. Pat. No. 837,831. In general the reactive esters of formula (II) can be prepared along the following sequence of reactions.

An appropriate 1-Ar-2-bromoethanone of formula (XXX) is subjected to a ketalization reaction with 1,2,3-propanetriol following methodologies analogous to those described in *Synthesis*, 1974, (I), 23.

In a preferred manner of carrying out the reaction both reactants are refluxed together for several hours with azeotropic water removal in an appropriate organic solvent, preferably in the presence of a simple alcohol, such as, for example, ethanol, propanol, butanol, pentanol and the like, and in the presence of an appropriate strong acid such as 4-methylbenzenesulfonic acid. Suitable organic solvents are, for example, aromatic hydrocarbons, such as benzene, methylbenzene, dimethylbenzene and the like and saturated hydrocarbons, such as cyclohexane.

The thus obtained dioxolane (XXXI) is then reacted with benzoyl chloride to obtain a benzoate of the formula (XXXII) and the latter is subsequently reacted with 1H-imidazole or 1H-1,2,4-triazole. Said reaction is preferably carried out by stirring and heating the reactants together in a suitable organic solvent, e.g., N,N-dimethylformamide, in the presence of an appropriate strong metal base, e.g., sodium methanolate, to obtain an intermediate of the formula (XXXIII). The desired reactive esters of formula (II) are then conveniently prepared by first hydrolyzing (XXXIV) in alkaline medium and thereafter converting the hydroxy group of the thus obtained (XXXV) into a reactive ester thereof according to methodologies generally known in the art. For example, methanesulfonates and 4-methylbenzenesulfonates are conveniently prepared by the reaction of the alcohol with methanesulfonyl chloride or 4-methylbenzenesulfonyl chloride and halides may be prepared by the reaction of the alcohol with an appropriate halogenating agent such as, for example, thionyl chloride, phosphor pentachloride, phosphor pentabromide, phosphoryl chloride and the like. When the reactive ester is an iodide, it is preferably prepared from the corresponding chloride or bromide by the replacement of that halogen with iodine.

The foregoing reactions may be illustrated as follows:



0006711

5

10

15

20

25

30

35

40


45

50

55

60

65



From formula (I) it is evident that the compounds of this invention have at least two asymmetric carbon atoms in their structures, namely those located in the 2- and 4- position of the dioxolane nucleus, and consequently they can exist under different stereochemically isomeric forms. The stereochemically isomeric forms of (I) and the pharmaceutically acceptable acid addition salts thereof are intended to be within the scope of this invention.

The diastereomeric racemates of (I), denoted as cis and trans forms respectively, according to the rules described in C.A., 76, Index Guide, Section IV, p. 85 (1972), may be obtained separately by conventional methods. Appropriate methods which may advantageously be employed therefore include, for example, selective crystallization and chromatographic separation, e.g. column-chromatography.

Since the stereochemical configuration is already fixed in a number of intermediate compounds,

e.g., in intermediates of the formulas (II), (IV), (VI) and (VIII) it is also possible to separate cis and trans forms at this or even an earlier stage, whereupon the corresponding forms of (I) may be derived therefrom in the previously indicated manner. The separation of cis and trans forms of such intermediates may be performed by conventional methods as described hereabove for the separation of cis and trans forms of the compounds (I).

It is evident that the cis and trans diastereomeric racemates may be further resolved into their optical isomers, cis(+), cis(-), trans(+) and trans(-) by the application of methodologies known to those skilled in the art.

The compounds of formula (I) and the pharmaceutically acceptable acid addition salts thereof are useful agents in combatting fungi and bacteria. For example, said compounds and acid addition salts thereof were found to be highly active against a wide variety of fungi such as, for example, *Microsporum canis*, *Ctenomyces mentagrophytes*, *Trichophyton rubrum*, *Phialophora verrucosa*, *Cryptococcus neoformans*, *Candida tropicalis*, *Candida albicans*, *Mucor* species, *Aspergillus fumigatus*, *Sporotrichum schenckii* and *Saprolegnia* species, and against bacteria such as, for example, *Erysipelotrix insidiosus*, *Staphylococci* such as *Staphylococcus hemolyticus* and *Streptococci* such as *Streptococcus pyogenes*. In view of their potent, local as well as systemic, antimicrobial activity the compounds of this invention constitute useful tools for the destruction or prevention of the growth of fungi and bacteria and more particularly they can effectively be used in the treatment of subjects suffering from such microorganisms.

The strong antimicrobial activity of the compounds (I) is clearly evidenced by the data obtained in the following experiments, which data are only given to illustrate the useful antimicrobial properties of all the compounds (I) and not to limit the invention either with respect to the scope of susceptible microorganisms nor with respect to the scope of the formula (I).

Experiment A:

Activity of compounds (I) against vaginal candidosis in rats.

Female Wistar rats of ± 100 g body weight are used. They are ovariectomized and hysterectomized and after three weeks of recovery, $100 \mu\text{g}$ of oestradiol undecylate in sesame oil is given subcutaneously once a week for 3 consecutive weeks. The thus induced pseudo-oestrus is controlled by microscopic examination of vaginal smears. Food and water are left available ad libitum. The rats are infected intravaginally with $8 \cdot 10^5$ cells of *Candida albicans*, grown on Sabouraud broth for 48 hours at 37°C and diluted with saline. The date of infection varies from day +25 to day +32 after surgical intervention, depending on the appearance of signs of induced pseudo-oestrus.

The drugs under investigation are administered orally once a day for two days starting from the day of infection. For each experiment there are placebo treated controls. The results are assessed by taking vaginal smears with sterile swabs on several days after the infection. The swabs are put into Sabouraud broth in petri-dishes and incubated for 48 hours at 37°C . If no growth of *Candida albicans* occurs, i.e., when the animals are negative at the end of the experiment, this is due to drug administration because it never happens in placebo-treated controls.

The table below gives the lowest oral doses of the drug under investigation which is found active at the 14th day after infection.

Experiment B:


Activity of compounds (I) against crop candidosis in turkeys.

Turkeys of 14 days old are infected in the crop with $4 \cdot 10^6$ *Candida albicans* cells, grown on Sabouraud broth for 48 hours at 37°C and diluted with saline. The volume of the inoculum is 1 ml. The drugs under investigation are premixed in 500 mg of lacton and thereafter admixed in 1000 g of meal without any additives. The concentration of the drug under investigation in the meal is expressed in mg/kg.

The animals are given the medicated feed for 13 consecutive days starting on the day of infection. At the end of the experiment all animals are sacrificed. At autopsy the crops are removed, emptied and grinded in an ultra-turrax mixer in 15 ml of sterile saline. Colony counting is done on Sabouraud agar and the results given in the table represent the ED_{50} , i.e., the dose of the drug whereby the crops of 50% of the animals are completely negative for *Candida albicans*.









The compounds listed in the table are intended to illustrate and not to limit the scope of the present invention.

0006711














cis

Y	Q	Vaginal candidosis in rats : lowest effective dose in mg/kg orally	Crop candidosis in turkeys : ED ₅₀ in mg/kg in feed
	CH	2.5	-
	N	2.5	-
	CH	1.25	-
	N	1.25	16
	CH	0.63	16
	N	0.63	-
	CH	2.5	-
	N	1.25	31
	CH	2.5	-

Y	Q	Vaginal candidosis in rats: lowest effective dose in mg/kg orally	Crop candidosis in turkeys: ED ₅₀ in mg/kg in feed
	N	≤0.63	-
	N	2.5	-
	N	2.5	-
	N	0.63	-
	CH	-	31
	CH	0.63	16
	N	≤0.63	16
	N	<2.5	-

0 006 711

	Y	Q	Vaginal candidosis in rats: lowest effective dose in mg/kg orally	Crop candidosis in turkeys: ED ₅₀ in mg/kg in feed
5		N	≥0.63	-
10		CH	1.0	16
15		CH	1.25	31
20		CH	0.63	-
25		N	<0.63	-
30		N	0.5	-
35		N	≥0.16	-
40		CH	1.25	-
45				
50				
55				

In view of their antifungal and antibacterial properties this invention provides valuable compositions comprising the subject compounds of formula (I) or acid addition salts thereof as the active ingredient in a solvent or a solid, semi-solid or liquid diluent or carrier, and, in addition, it provides an effective method of combatting fungal or bacterial growth by use of an effective antifungal or antibacterial amount of such compounds (I) or salts thereof. Antifungal and antibacterial compositions comprising an effective amount of an active compound (I), either alone or in combination with other active therapeutic ingredients, in admixture with suitable carriers may be readily prepared according to conventional pharmaceutical techniques for the usual routes of administration.

Preferred compositions are in dosage unit form, comprising per dosage unit an effective quantity of the active ingredient in admixture with suitable carriers. Although the amount of the active ingredient per unit dosage may vary within rather wide limits, dosage units comprising from 50 to 500 mg and more particularly from 100 to 250 mg of the active ingredient are preferred.

5 The following examples are intended to illustrate and not to limit the scope of the present invention.

Unless otherwise stated all parts therein are by weight.

A) Preparation of intermediates:

10

Example I

A mixture of 13.4 parts of 1-(4-methoxyphenyl)piperazine dihydrochloride, 7.9 parts of 1-chloro-4-nitrobenzene, 10 parts of potassium carbonate and 90 parts of N,N-dimethylformamide is stirred and refluxed overnight. The reaction mixture is diluted with water and the product is extracted twice with trichloromethane. The combined extracts are dried, filtered and evaporated. The residue is triturated in 15 4-methyl-2-pentanone. The product is filtered off and crystallized from 1,4-dioxane, yielding 10.5 parts (67%) of 1-(4-methoxyphenyl)-4-(4-nitrophenyl)piperazine; mp. 195.1°C.

A mixture of 12 parts of 1-(4-methoxyphenyl)-4-(4-nitrophenyl)piperazine, 200 parts of methanol and 225 parts of tetrahydrofuran is hydrogenated at normal pressure and at room temperature with 20 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen is taken up, the catalyst is filtered off and washed with N,N-dimethylacetamide. The filtrate is poured onto water. The precipitated product is filtered off and crystallized from 1-butanol, yielding 8 parts (74%) of 4-[4-(4-methoxyphenyl)-1-piperazinyl]benzenamine; mp. 191.8°C.

25

Example II

To a stirred and cooled (ice-bath) mixture of 5 parts of N,N'-methanetetraylbis[cyclohexanamine], 25.2 parts of carbon disulfide and 40 parts of pyridine are added 6 parts of 4-[4-(4-methoxyphenyl)-1-piperazinyl]benzenamine and the whole is stirred first for 1 hour in an ice-bath and further for 2 hours at room temperature. 35 Parts of 2,2'-oxybispropane are added and the whole is 30 stirred for 30 minutes. The precipitated product is filtered off and crystallized from 4-methyl-2-pentanone. The product is filtered off again and recrystallized from 1,4-dioxane, yielding 2.45 parts of 1-(4-isothiocyanatophenyl)-4-(4-methoxyphenyl)piperazine; mp. 180.6°C.

A mixture of 47.8 parts of 1-(4-isothiocyanatophenyl)-4-(4-methoxyphenyl)piperazine, 100 parts of hydrazine hydrate and 400 parts of 1,4-dioxane is stirred and refluxed for 1 hour. The reaction 35 mixture is cooled and poured onto water. The precipitated product is filtered off, washed with water and with methanol and dried, yielding 46 parts (89%) of N-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]hydrazinecarbothioamide.

Example III

A mixture of 23 parts of N-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]hydrazinecarbothioamide, 23 parts of methanimidamide acetate and 80 parts of 1-butanol is stirred and refluxed for 1 hour. The reaction mixture is cooled and poured onto water. 2,2'-oxybispropane is added. The precipitated product is filtered off, washed with water and with methanol and crystallized from 1-butanol, yielding 17.7 parts of 4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]-4H-1,2,4-triazole-3-thiol; mp. 45 231.9°C.

Following the same procedure and using an equivalent amount of ethanimidamide hydrochloride in place of the methanimidamide acetate used therein, there is obtained 4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-5-methyl-4H-1,2,4-triazole-3-thiol; mp. 260.3°C.

50

Example IV

A mixture of 9 parts of 4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-4H-1,2,4-triazole-3-thiol, 2 parts of sodium hydroxide and 160 parts of methanol is stirred and warmed till all solid enters solution. Then there are added 3.3 parts of dimethyl sulfate and stirring is continued for 3 hours at room temperature. The reaction mixture is poured onto water. The precipitated product is filtered off and 55 crystallized from 1-butanol, yielding 5.3 parts of 1-(4-methoxyphenyl)-4-[4-[3-(methylthio)-4H-1,2,4-triazol-4-yl]phenyl]piperazine; mp. 180°C.

In a similar manner there is prepared:

60 1-(4-methoxyphenyl)-4-[4-[3-methyl-5-(methylthio)-4H-1,2,4-triazol-4-yl]phenyl]piperazine dihydrochloride; mp. 210°C.

Example V

A mixture of 50 parts of 2-(4-nitrophenyl)hydrazinecarbothioamide and 270 parts of 65 methylbenzene is distilled azeotropically to dry. Then there are added 26 parts of acetic acid anhydride

and the whole is stirred and refluxed for 3 hours. The reaction mixture is cooled. The precipitated product is filtered off, washed with 2-propanol and crystallized from ethanol. It is filtered off again and dried at 100°C, yielding 31.5 parts of acetic acid, 2-(aminothioxomethyl)-1-(4-nitrophenyl)hydrazide; mp. 241.5°C.

Following the same acetylation-procedure and using equivalent amounts of the appropriate starting materials there are also prepared:

butanoic acid, 2-(aminothioxomethyl)-1-(4-nitrophenyl)hydrazide monohydrate; mp. 197.2°C; and propanoic acid, 2-(aminothioxomethyl)-1-(4-nitrophenyl)hydrazide; mp. 216.1°C.

Example VI

40 Parts of acetic acid, 2-(aminothioxomethyl)-1-(4-nitrophenyl)hydrazide are dissolved in a mixture of 10 parts of sodium hydroxide and 400 parts of water and the solution is stirred for 30 minutes at room temperature. The reaction mixture is acidified with concentrated hydrochloric acid. The precipitated product is filtered off, washed with water and with 2-propanol and crystallized from 1,4-dioxane, yielding 22.4 parts of 5-methyl-1-(4-nitrophenyl)-1H-1,2,4-triazole-3-thiol; mp. 202.1°C.

In a similar manner there are also prepared:

1-(4-nitrophenyl)-5-propyl-1H-1,2,4-triazole-3-thiol; mp. 190.7°C; and

5-ethyl-1-(4-nitrophenyl)-1H-1,2,4-triazole-3-thiol; mp. 206.1°C.

Example VII

To 80 parts of methanol are added 4.7 parts of 5-methyl-1-(4-nitrophenyl)-1H-1,2,4-triazole-3-thiol and 1.2 parts of sodium hydroxide and the whole is stirred till all solid enters solution. Then there are added 2.66 parts of dimethyl sulfate and stirring is continued for 1 hour at room temperature. 100 parts of water are added. The precipitated product is filtered off, washed with water, dried, and crystallized from 2,2'-oxybispropane, yielding 3.3 parts (66%) of 5-methyl-3-(methylthio)-1-(4-nitrophenyl)-1H-1,2,4-triazole; mp. 121—125°C.

Following the same S-methylation procedure and using equivalent amounts of the appropriate starting materials there are also prepared:

5-ethyl-3-(methylthio)-1-(4-nitrophenyl)-1H-1,2,4-triazole; mp. 77.8°C; and

3-(methylthio)-1-(4-nitrophenyl)-1H-1,2,4-triazole; mp. 140°C.

Example VIII

A mixture of 2.5 parts of 5-methyl-3-(methylthio)-1-(4-nitrophenyl)-1H-1,2,4-triazole and 120 parts of methanol is hydrogenated at normal pressure and at room temperature with 2 parts of platinum-on-charcoal catalyst 10%. After the calculated amount of hydrogen is taken up, the catalyst is filtered off and the filtrate is evaporated. The residue is crystallized from a mixture of 4-methyl-2-pentanone and petroleum ether. The product is filtered off and dried, yielding 1.5 parts (68%) 4-[5-methyl-3-(methylthio)-1H-1,2,4-triazol-1-yl]benzenamine; mp. 130—136°C.

Following the same hydrogenation-procedure there is also prepared:

4-[3-(methylthio)-1H-1,2,4-triazol-1-yl]benzenamine as a residue.

Example IX

A mixture of 41 parts of 5-ethyl-3-(methylthio)-1-(4-nitrophenyl)-1H-1,2,4-triazole and 80 parts of methanol is hydrogenated at normal pressure and at room temperature with 1 part of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen is taken up, the catalyst is filtered off and the filtrate is evaporated. The residue is crystallized from 1,1'-oxybisbutane. The product is filtered off and dried, yielding 33 parts (91%) of 4-[5-ethyl-3-(methylthio)-1H-1,2,4-triazol-1-yl]benzamine; mp. 131.7°C.

In a similar manner there is also prepared:

4-(2-methyl-1H-imidazol-1-yl)benzenamine; mp. 105°C.

Example X

A mixture of 20 parts of 4-[5-methyl-3-(methylthio)-1H-1,2,4-triazol-1-yl]benzenamine, 15 parts of Raney-nickel catalyst and 400 parts of methanol is stirred and refluxed for 2 hours. The Raney-nickel is filtered off and another 15 parts of the catalyst are added. Stirring at reflux is continued for 4 hours. The reaction mixture is filtered, washed on the filter with methanol and the filtrate is evaporated. The residue is crystallized from a mixture of 4-methyl-2-pentanone, 2,2'-oxybispropane and petroleum ether. The product is filtered off and dried, yielding 7.6 parts (47%) of 4-(5-methyl-1H-1,2,4-triazol-1-yl)benzenamine; mp. 145°C.

Example XI

A mixture of 35 parts of 1-(4-nitrophenyl)-5-propyl-1H-1,2,4-triazole-3-thiol, 83 parts of concentrated nitric acid solution and 150 parts of water is stirred and warmed to 60°C. While stirring, the mixture is allowed to cool to room temperature and the whole is further stirred overnight at room temperature. The precipitated product is filtered off, washed with water and added to a hot solution of 20 parts of potassium carbonate in 200 parts of water at 100°C. The reaction mixture is allowed to cool to room temperature while stirring. The precipitated product is filtered off, dried and crystallized from a mixture of 4-methyl-2-pentanone and 2,2'-oxybispropane. The product is filtered off and recrystallized from 4-methyl-2-pentanone, yielding 19.8 parts of 3,3'-dithiobis[1-(4-nitrophenyl)-5-propyl-1H-1,2,4-triazole]; mp. 171.5°C.

20 Parts of 3,3'-dithiobis[1-(4-nitrophenyl)-5-propyl-1H-1,2,4-triazole] are dissolved in 100 parts of acetic acid while stirring and warming. Then there are added dropwise 55 parts of hydrogen peroxide solution 30%; reflux temperature is reached. Upon completion, stirring at reflux is continued for 1 hour. The reaction mixture is cooled and poured onto a mixture of crushed ice and a sodium hydroxide solution 50%. The precipitated product is filtered off and dissolved in dichloromethane. The solution is washed with a sodium sulfite solution, dried, filtered and evaporated. The residue is purified by column-chromatography over silica gel using trichloromethane as eluent. The pure fractions are collected and the eluent is evaporated. The residue is converted into the hydrochloride salt in 2-propanol. The salt is filtered off and crystallized from ethanol, yielding 3.9 parts (19%) of 1-(4-nitrophenyl)-5-propyl-1H-1,2,4-triazole monohydrochloride; mp. 178.7°C.

A mixture of 38.3 parts of 1-(4-nitrophenyl)-5-propyl-1H-1,2,4-triazole monohydrochloride and 400 parts of methanol is hydrogenated at normal pressure and at room temperature with 3 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen is taken up, the catalyst is filtered off and the filtrate is evaporated. The residue is dissolved in water and neutralized with sodium hydrogen carbonate. The product is extracted with dichloromethane. The extract is washed with water, dried, filtered and evaporated. The residue is converted into the hydrochloride salt in 2-propanol. The salt is filtered off and dried, yielding 35 parts (91%) of 4-(5-propyl-1H-1,2,4-triazol-1-yl)-benzenamine dihydrochloride.

Example XII

A mixture of 4 parts of N-(4-nitrophenyl)hydrazinecarboxamide, 5 parts of ethanimidamide hydrochloride and 5 parts of sodium acetate is stirred and heated for 4 hours at 140°C. The reaction mixture is cooled, water is added and the whole is stirred till the product is crystallized. It is filtered off and recrystallized from 2-propanol, yielding 1.5 parts (34%) of 2,4-dihydro-5-methyl-4-(4-nitrophenyl)-3H-1,2,4-triazol-3-one; mp. 226.1°C.

To a stirred solution of 13.5 parts of 2,4-dihydro-5-methyl-4-(4-nitrophenyl)-3H-1,2,4-triazol-3-one in 100 parts of dimethyl sulfoxide are added 2 parts of sodium hydride dispersion 78% and the whole is stirred till foaming has ceased. Then there are added dropwise 8.1 parts of dimethyl sulfate. Upon completion, stirring is continued for 3 hours at room temperature. The reaction mixture is poured onto water and the product is extracted three times with trichloromethane. The combined extracts are washed with water, dried, filtered and evaporated. The residue is crystallized from a mixture of 2-propanol and 2,2'-oxybispropane. The product is filtered off and recrystallized from 4-methyl-2-pentanone, yielding 6.3 parts of 2,4-dihydro-2,5-dimethyl-4-(4-nitrophenyl)-3H-1,2,4-triazol-3-one; mp. 153.2°C.

A mixture of 9 parts of 2,4-dihydro-2,5-dimethyl-4-(4-nitrophenyl)-3H-1,2,4-triazol-3-one and 200 parts of methanol is hydrogenated at normal pressure and at room temperature with 3 parts of Raney-nickel catalyst. After the calculated amount of hydrogen is taken up, the catalyst is filtered off and the filtrate is evaporated. The residue is triturated in 2,2'-oxybispropane. The product is filtered off and dried, yielding 7.5 parts (95%) of 4-(4-aminophenyl)-2,4-dihydro-2,5-dimethyl-3H-1,2,4-triazol-3-one; mp. 160°C.

Example XIII

A mixture of 53 parts of N-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]hydrazinecarboxamide, 53 parts of ethanimidamide hydrochloride and 135 parts of N,N-dimethylformamide is stirred and heated for 3 hours at 130°C. The reaction mixture is cooled and poured onto water. The precipitated product is filtered off, washed with water and with methanol, and crystallized from N,N-dimethylformamide. The product is filtered off and recrystallized from 1,4-dioxane, yielding 19.5 parts of 2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-5-methyl-3H-1,2,4-triazol-3-one; 298.4°C.

Example XIV

19.2 Parts of 2,4-dihydro-4-[4-[4-methoxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one are dissolved in 450 parts of dimethyl sulfoxide at about 100°C. Then there are added 3.1 parts of sodium hydride dispersion 50% and the whole is stirred till a temperature of about 50°C is reached. 8.2 Parts of dimethyl sulfate are added and stirring is continued overnight at room temperature. The

reaction mixture is poured onto water and the product is extracted with trichloromethane. The extract is dried, filtered and evaporated. The residue is purified by column-chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions are collected and the eluent is evaporated. The residue is crystallized from 1-butanol, yielding 5.8 parts of 2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-piperazinyl]phenyl]-2-methyl-3H-1,2,4-triazol-3-one; mp. 245.7°C.

Example XV

10 Parts of 2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one are dissolved in 300 parts of dimethyl sulfoxide at 100°C. Then there are added 1.6 parts of sodium hydride dispersion 50% and stirring is continued while the mixture is allowed to cool to about 50°C. 3.9 Parts of 1-bromopropane are added and the whole is stirred overnight at room temperature. The reaction mixture is poured onto water and the product is extracted with trichloromethane. The extract is washed with water, dried, filtered and evaporated. The residue is purified by column-chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions are collected and the eluent is evaporated. The residue is triturated in 2-propanol. The product is filtered off and dried, yielding 7.5 parts (65%) of 2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-2-propyl-3H-1,2,4-triazol-3-one.

Following the same N-alkylation-procedure and using equivalent amounts of the appropriate starting materials there are prepared:

2-ethyl-2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-5-methyl-3H-1,2,4-triazol-3-one; mp. 179.8°C.

2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-5-methyl-2-propyl-3H-1,2,4-triazol-3-one; mp. 144.5°C; and

2-ethyl-2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one; mp. 210.2°C.

Example XVI

A mixture of 12.5 parts of N,N-bis(2-chloroethyl)-4-methoxybenzenamine, 8 parts of 4-(1H-pyrazol-1-yl)benzenamine, 2 parts of potassium iodide, 80 parts of 2-propanone and 100 parts of water is stirred and refluxed for 24 hours. The reaction mixture is cooled. The precipitated product is filtered off (the filtrate is set aside), washed with water and with 2-propanone, yielding a first crude fraction of 6 parts. The filtrate (see above) is neutralized with a sodium hydrogen carbonate solution and extracted with trichloromethane. The extract is dried, filtered and evaporated. The residue is triturated in 2-propanol. The product is filtered off and washed with methanol, yielding a second crude fraction of 2 parts. The combined crude crops (resp. 6 and 2 parts) are crystallized from 1-butanol, yielding 7.1 parts of 1-(4-methoxyphenyl)-4-[4-(1H-pyrazol-1-yl)-phenyl]piperazine; mp. 207.7°C.

Following the same procedure and using equivalent amounts of the appropriate starting materials there are also prepared:

1-[4-(1H-imidazol-1-yl)phenyl]-4-(4-methoxyphenyl)piperazine; mp. 255—256°C.

1-(4-methoxyphenyl)-4-[4-(1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 230.3°C.

1-(4-methoxyphenyl)-4-[4-[3-(methylthio)-1H-1,2,4-triazol-1-yl]phenyl]piperazine; mp. 186.5°C.

1-(4-methoxyphenyl)-4-[4-[5-methyl-3-(methylthio)-1H-1,2,4-triazol-1-yl]phenyl]piperazine; mp. 153.3°C.

1-(4-methoxyphenyl)-4-[4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 191.1°C.

2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-2,5-dimethyl-3H-1,2,4-triazol-3-one; mp. 196.7°C.

1-(4-methoxyphenyl)-4-[4-(5-propyl-1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 196.3°C.

1-[4-[5-ethyl-3-(methylthio)-1H-1,2,4-triazol-1-yl]phenyl]-4-(4-methoxyphenyl)piperazine; mp. 142.3°C; and

1-(4-methoxyphenyl)-4-[4-(2-methyl-1H-imidazol-1-yl)phenyl]piperazine; mp. 178.5°C.

Example XVII

A mixture of 6 parts of 4-[4-(4-methoxyphenyl)-1-piperazinyl]benzenamine, 3.6 parts of phenyl carbonochloridate, 75 parts of pyridine and 98 parts of dichloromethane is stirred and warmed till all solid enters solution. Stirring is continued for 30 minutes at room temperature. The reaction mixture is poured onto 500 parts of water and 210 parts of 2,2'-oxybispropane are added. The whole is stirred for a while.

The precipitated product is filtered off and crystallized from 1-butanol, yielding 5.2 parts (61%) of phenyl[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]carbamate; mp. 204.5°C.

A mixture of 3.2 parts of phenyl[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]carbamate, 50 parts of hydrazine hydrate and 100 parts of 1,4-dioxane is stirred and refluxed for 3 hours. The reaction

mixture is cooled and poured onto water. The precipitated product is filtered off and crystallized from N,N-dimethylformamide, yielding 1.7 parts (63%) of N-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]hydrazinecarboxamide; mp. +300°C.

- 5 A mixture of 3.4 parts of N-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]hydrazinecarboxamide, 3 parts of methanimidamide acetate and 10 parts of dimethyl sulfoxide is stirred and heated for 2 hours at 100°C. The reaction mixture is cooled and poured onto a mixture of 4-methyl-2-pentanone and 2,2'-oxybispropane. The precipitated product is filtered off and crystallized from N,N-dimethylformamide (activated charcoal), yielding 1 part (28%) of 2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one; mp. +300°C.

10

Example XVIII

- 15 A mixture of 30 parts of 4-[4-(4-methoxyphenyl)-1-piperazinyl]benzenamine and 300 parts of a hydrobromic acid solution 48% in water is stirred and refluxed for 10 days. The reaction mixture is evaporated and the residue is alkalized with sodium hydroxide. The mixture is filtered and the filtrate is acidified with acetic acid. The precipitated product is filtered off and crystallized from 1,4-dioxane, yielding 12 parts (44%) of 4-[4-(4-aminophenyl)-1-piperazinyl]phenol.

Following the same procedure and using equivalent amounts of the appropriate starting materials there are also prepared:

- 20 4-[4-[4-(1H-pyrazol-1-yl)phenyl]-1-piperazinyl]phenol;
4-[4-[4-(1H-imidazol-1-yl)phenyl]-1-piperazinyl]phenol; mp. >260°C;
4-[4-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1-piperazinyl]phenol; mp. 276.6°C;
4-[4-[4-[3-(methylthio)-1H-1,2,4-triazol-1-yl]phenyl]-1-piperazinyl]phenol; mp. 225.5°C;
4-[4-[4-[5-methyl-3-(methylthio)-1H-1,2,4-triazol-1-yl]phenyl]-1-piperazinyl]phenol;
25 mp. 255.8°C;
4-[4-[4-[3-methyl-5-(methylthio)-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenol;
4-[4-[4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-piperazinyl]phenol; mp. 281.1°C;
4-[4-[4-[3-(methylthio)-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenyl;
2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-2,5-dimethyl-3H-1,2,4-triazol-3-one;
30 mp. +260°C;
2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-2-propyl-3H-1,2,4-triazol-3-one;
4-[4-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-1-piperazinyl]phenol; mp. +300°C;
4-[4-[4-[5-ethyl-3-(methylthio)-1H-1,2,4-triazol-1-yl]phenyl]-1-piperazinyl]phenol;
mp. 232.6°C;
35 2-ethyl-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-5-methyl-3H-1,2,4-triazol-3-one; mp. 287.8°C;
2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-5-methyl-2-propyl-3H-1,2,4-triazol-3-one; mp. 258.2°C;
2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-2-methyl-3H-1,2,4-triazol-3-one;
40 2-ethyl-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one; mp. 217°C; and
4-[4-[4-(5-propyl-1H-1,2,4-triazol-1-yl)phenyl]-1-piperazinyl]phenol; mp. 225.6°C.

B. Preparation of final compounds.

45

Example XIX

- To a stirred solution of 3 parts of 4-[4-(4-aminophenyl)-1-piperazinyl]phenol in 50 parts of dimethyl sulfoxide are added 0.5 parts of a sodium hydride dispersion 50%. The whole is stirred at 50°C till foaming has ceased. Then there are added 4.1 parts of *cis*-2-(2,4-dichlorophenyl)-2-(1H-imidazol-2-ylmethyl)-1,3-dioxolan-4-ylmethyl methanesulfonate and stirring is continued for 2 hours at 70°C. The reaction mixture is cooled and poured onto water. The product is extracted with dichloromethane. The extract is washed with a diluted sodium hydroxide solution, dried, filtered and evaporated. The residue is purified by column-chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions are collected and the
50 eluent is evaporated. The residue is crystallized from 2-propanol. The product is filtered off and dried, yielding 1.3 parts (22%) of *cis*-4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-1-piperazinyl]benzenamine; mp. 174.4°C.

55

Example XX

- 60 To a solution of 3.2 parts of 4-[4-[4-(1H-pyrazol-1-yl)phenyl]-1-piperazinyl]phenol in 100 parts of dimethyl sulfoxide are added 0.32 parts of a sodium hydride dispersion 78% and the whole is stirred at 50°C till foaming has ceased. Then 4.1 parts of *cis*-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethyl methanesulfonate are added and stirring is continued for 3 hours at 100°C. The reaction mixture is cooled, poured onto water and the product is extracted with dichloromethane. The extract is washed with diluted sodium hydroxide solution, dried, filtered and evaporated.
65

The residue is purified by column-chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions are collected and the eluent is evaporated.

The residue is purified again by column-chromatography over silica gel using a mixture of methylbenzene and ethanol (95:5 by volume) as eluent. The pure fractions are collected and the eluent is evaporated. The residue is crystallized from ethylbenzene, yielding 2.2 parts (34%) of: *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(1H-pyrazol-1-yl)phenyl]piperazine; mp. 195.1°C.

Following the same procedure and using equivalent amounts of the appropriate starting materials there are also prepared:

- 10 *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(1H-imidazol-1-yl)phenyl]piperazine; mp. 166.7°C.
- cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 175.3°C.
- 15 *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-[3-(methylthio)-1H-1,2,4-triazol-1-yl]phenyl]piperazine; mp. 178.3°C.
- cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-[3-methyl-5-(methylthio)-4H-1,2,4-triazol-4-yl]phenyl]piperazine; mp. 127.8°C.
- cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(5-methyl-3-(methylthio)-1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 188.9°C.
- 20 *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-[3-(methylthio)-4H-1,2,4-triazol-4-yl]phenyl]piperazine; mp. 176.4;
- cis*-4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]-phenyl]-2,4-dihydro-2,5-dimethyl-3H-1,2,4-triazol-3-one; mp. 149.3°C;
- 25 *cis*-4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]-phenyl]-2,4-dihydro-2-propyl-3H-1,2,4-triazol-3-one; mp. 185.7°C;
- cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 154.1°C;
- cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(2-methyl-1H-imidazol-1-yl)phenyl]piperazine; mp. 180.1°C;
- 30 *cis*-4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]-phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one; mp. 212.8°C;
- cis*-4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one; mp. 204.7°C;
- 35 *cis*-4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-5-methyl-2-propyl-3H-1,2,4-triazol-3-one monohydrate; mp. 153.9°C;
- cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-[5-ethyl-3-(methylthio)-1H-1,2,4-triazol-1-yl]phenyl]piperazine; mp. 136.3°C;
- 40 *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(5-propyl-1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 150.4°C; and
- cis*-4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2-ethyl-2,4-dihydro-5-methyl-3H-1,2,4-triazol-3-one monohydrate; mp. 135.5°C.

45

Example XXI

A mixture of 2 parts of sodium azide, 5.8 parts of *cis*-4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]benzeneamine, 4 parts of 1,1',1''-[methylidynetris(oxy)]trisethane and 50 parts of acetic acid is stirred and heated overnight at 70°C. The reaction mixture is cooled and neutralized with a potassium carbonate solution. The product is extracted with dichloromethane. The extract is dried and evaporated. The residue is purified by column-chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions are collected and the eluent is evaporated. The residue is crystallized from 1-butanol. The product is filtered off and dried, yielding 3.8 parts (60%) of *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(1H-tetrazol-1-yl)phenyl]piperazine; mp. 201.3°C.

55

Example XXII

To a stirred solution of 8 parts of 4-[4-(4-aminophenyl)-1-piperazinyl]phenol in 100 parts of dimethyl sulfoxide are added 1.5 parts of sodium hydride dispersion 50% and stirring is continued till foaming has ceased. Then there are added 12.3 parts of *cis*-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethyl]methanesulfonate and the whole is stirred and heated for 4 hours at 50°C. The reaction mixture is cooled and poured onto water. The product is extracted three times with dichloromethane. The combined extracts are washed with a diluted sodium hydroxide solution and treated with activated charcoal. The latter is filtered off and the filtrate is evaporated. The residue is purified by column-chromatography over silica gel using a mixture of trichloromethane and

65

methanol (98:2 by volume) as eluent. The pure fractions are collected and the eluent is evaporated. The residue is crystallized from 1-butanol, yielding 5.1 parts of *cis*-4-[4-[4-(2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]benzenamine; mp. 186.8°C.

5 Example XXIII

To a stirred solution of 3 parts of 4-[4-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1-piperazinyl]phenol in 100 parts of dimethyl sulfoxide are added 0.3 parts of sodium hydride dispersion 78% and the whole is stirred at 50°C till foaming has ceased. Then there are added 3.7 parts of *cis*-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]methanesulfonate and stirring is continued
10 for 3 hours at 100°C. The reaction mixture is cooled and poured onto water. The product is extracted three times with dichloromethane. The combined extracts are washed with a diluted sodium hydroxide solution, dried, filtered and evaporated. The residue is crystallized from 1-butanol. The product is filtered off and dried, yielding 4.3 parts (75%) of *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp.
15 219.6°C.

Following the same procedure and using equivalent amounts of the appropriate starting materials there are also prepared:

- cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-(1H-pyrazol-1-yl)phenyl]piperazine; mp. 183.3°C.
20 *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(1H-imidazol-1-yl)phenyl]piperazine; mp. 194.3°C.
cis-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 166.5°C.
25 *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(3-(methylthio)-1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 153.9°C.
cis-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(5-methyl-3-(methylthio)-1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 164.1°C.
cis-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-3-(methylthio)-4H-1,2,4-triazole; mp. 147—152.6°C.
30 *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(3-methyl-5-(methylthio)-4H-1,2,4-triazol-4-yl)phenyl]piperazine; mp. 118.3°C.
cis-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]-phenyl]-2,4-dihydro-2,5-dimethyl-3H-1,2,4-triazol-3-one monohydrate; mp.
35 161.9°C;
cis-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-propyl-3H-1,2,4-triazol-3-one; mp. 167.3°C;
cis-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(2-methyl-1H-imidazol-1-yl)phenyl]piperazine; mp. 175.6°C;
40 *cis*-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]-phenyl]-2,4-dihydro-2-methyl-3H-1,2,4-triazol-3-one; mp. 193.8°C;
cis-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]-phenyl]-2-ethyl-2,4-dihydro-5-methyl-3H-1,2,4-triazol-3-one; mp. 178.3°C;
cis-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]-phenyl]-2,4-dihydro-5-methyl-2-propyl-3H-1,2,4-triazol-3-one monohydrate;
45 mp. 165.5°C;
cis-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one; mp. 186°C; and
cis-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-
50 4-[4-(5-propyl-1H-1,2,4-triazol-1-yl)phenyl]piperazine; mp. 140.9°C.

Example XXIV

55 A mixture of 4 parts of *cis*-4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]benzenamine, 0.5 parts of sodium azide, 1.08 parts of 1,1',1''-[methylidynetris(oxy)]-trisethane and 50 parts of acetic acid is stirred for 5 hours at 70°C. Another 0.5 parts of sodium azide and 1.08 parts of 1,1',1''-[methylidynetris(oxy)]trisethane are added and stirring at 70°C is continued for 15 hours. The reaction mixture is cooled and poured onto a
60 mixture of potassium carbonate and water. The product is extracted with dichloromethane. The extract is dried, filtered and evaporated. The residue is purified by column-chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions are collected and the eluent is evaporated. The residue is crystallized from 1-butanol, yielding 2.1 parts (48%) of
65 *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(1H-tetrazol-1-yl)phenyl]piperazine; mp. 192.5°C.

1. The
-(1H-
8°C.

rol in
ole is
enyl)-
inued
acted
oxide
ct is
iazol-
mp.

erials

l)-4-

l)-

yl)-

l)-

yl)-4-

l)-4-

mp.

l)-

C;

se;

l)-

-1,3-
ts of
0°C.
dded
to a
tract
sing
are
parts
4-yl-

Example XXV

To a stirred mixture of 5.7 parts of *cis*-4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]benzenamine and 100 parts of acetic acid are added 1.5 parts of tetrahydro-2,5-dimethoxyfuran at 50°C. The whole is stirred and refluxed for 5 minutes. The reaction mixture is poured onto crushed ice and the whole is neutralized with a sodium hydroxide solution 50%. The product is extracted with dichloromethane. The extract is treated with activated charcoal. The latter is filtered off and the filtrate is evaporated. The residue is crystallized from 1-butanol, yielding 3.3 parts (52%) of *cis*-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(1H-pyrrol-1-yl)phenyl]piperazine; mp. 188.9°C.

In a similar manner there is also prepared:

cis-1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(1H-pyrrol-1-yl)phenyl]piperazine; mp. 184.9°C.

Example XXVI

A mixture of 40 parts of ethanimidamide hydrochloride, 20 parts of *cis*-N-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]hydrazinecarboxamide, 40 parts of sodium acetate and 90 parts of N,N-dimethylformamide is stirred and heated for 4 hours at 130°C. The reaction mixture is cooled and 100 parts of water are added. The precipitated product is filtered off, washed with water and with 2-propanol, and crystallized from 1-butanol, yielding 9 parts (44%) of *cis*-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-5-methyl-3H-1,2,4-triazol-3-one 2-propanolate (2:1); mp. 295.7°C.

In a similar manner there are also prepared:

cis-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-5-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one; mp. 275.6°C; and *cis*-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one; mp. 255°C.

Example XXVII

A mixture of 1.31 parts of 2-bromopropane, 5 parts of *cis*-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one and 100 parts of dimethyl sulfoxide is stirred at 50°C and 0.4 parts of sodium hydride dispersion 50% are added. After stirring for 1 hour at 50°C, another 1.31 parts of 2-bromopropane and 0.4 parts of sodium hydride dispersion 50% are added and stirring is continued for 1 hour at 50°C. The reaction mixture is cooled and poured onto water. The product is extracted with dichloromethane. The extract is washed with water, dried, filtered and evaporated. The residue is purified by column-chromatography over silica gel using a mixture of trichloromethane and methanol (99:1 by volume) as eluent. The pure fractions are collected and the eluent is evaporated. The residue is crystallized from 4-methyl-2-pentanone, yielding 2 parts (37%) of *cis*-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylethyl)-3H-1,2,4-triazol-3-one; mp. 222.1°C.

In a similar manner there are also prepared:

cis-2-butyl-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one; mp. 199.2°C; and *cis*-4-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-5-ethyl-2,4-dihydro-2-propyl-3H-1,2,4-triazol-3-one; mp. 170.4°C.

Example XXVIII

Following the procedure described in Example XIX there are also prepared:

trans-3-[4-[4-[2-(5-bromo-2-thienyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]benzenamine;
4-[4-[4-[2-(2-chloro-6-methylphenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]benzenamine;
4-[4-[4-[2-(1H-imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]benzenamine;
3-[4-[4-[2-(5-chloro-2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]benzenamine.

Example XXIX

Following the procedure described in Example XX there are also prepared:

- 5 cis-1-[4-[2-(3-ethoxyphenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(3-methyl-1H-pyrrol-1-yl)-phenyl]piperazine;
 1-[3-[2-(1H-imidazol-1-ylmethyl)-2-(2-thienyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[3-(4-phenyl-1H-pyrrol-1-yl)phenyl]piperazine;
 trans-1-[4-[2-(4-bromophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(1H-pyrrol-1-yl)phenyl]piperazine;
 10 cis-1-[3-[2-(4-bromo-2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(2,5-diethyl-1H-pyrrol-1-yl)phenyl]piperazine;
 4-[3-(4-methyl-1H-pyrazol-1-yl)phenyl]-1-[4-[2-(2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-piperazine;
 trans-1-[4-[2-(5-bromo-2-thienyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(2-ethylthio-4-phenyl-1H-imidazol-1-yl)phenyl]piperazine;
 15 cis-4-[4-(5-ethyl-2-mercapto-1H-imidazol-1-yl)phenyl]-1-[3-[2-phenyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-piperazine;
 1-[4-[2-(4-bromo-2-ethoxyphenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[3-(5-phenyl-1H-1,2,4-triazol-1-yl)phenyl]piperazine;
 20 trans 1-[3-[2-(5-chloro-2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[2-(3-methylthio-5-pentyl-4H-1,2,4-triazol-4-yl)phenyl]piperazine;
 4-[4-[4-[2-(2,6-diethoxyphenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-phenylmethyl-3H-1,2,4-triazol-3-one;
 cis 4-[4-[4-[2-(2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-methyl-5-phenylmethyl-3H-1,2,4-triazol-3-one;


Example XXX

Following the procedure described in Example XXI there are also prepared:

- 30 1-[4-[2-(4-fluorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(5-methylthio-1H-tetrazol-1-yl)-phenyl]piperazine;
 trans 1-[4-[2-(5-chloro-2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(5-phenylethyl-1H-tetrazol-1-yl)phenyl]piperazine.

Claims

- 40 1. A chemical compound selected from the group consisting of an azole derivative having the formula:



and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein:

- 60 Q is a member selected from the group consisting of CH and N;
 Ar is a member selected from the group consisting of phenyl, thienyl, halothienyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of halo, C₁—C₆ alkyl, C₁—C₆ alkoxy and trifluoromethyl; and
 65 the radical Y is a member selected from the group consisting of



Example XXIX

Following the procedure described in Example XX there are also prepared:

- cis-1-[4-[2-(3-ethoxyphenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(3-methyl-1H-pyrrol-1-yl)-phenyl]piperazine;
 1-[3-[2-(1H-imidazol-1-ylmethyl)-2-(2-thienyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[3-(4-phenyl-1H-pyrrol-1-yl)phenyl]piperazine;
 trans-1-[4-[2-(4-bromophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(1H-pyrrol-1-yl)phenyl]piperazine;
 cis-1-[3-[2-(4-bromo-2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]-phenyl]-4-[4-(2,5-diethyl-1H-pyrrol-1-yl)phenyl]piperazine;
 4-[3-(4-methyl-1H-pyrazol-1-yl)phenyl]-1-[4-[2-(2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-piperazine;
 trans-1-[4-[2-(5-bromo-2-thienyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(2-ethylthio-4-phenyl-1H-imidazol-1-yl)phenyl]piperazine;
 cis-4-[4-(5-ethyl-2-mercapto-1H-imidazol-1-yl)phenyl]-1-[3-[2-phenyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-piperazine;
 1-[4-[2-(4-bromo-2-ethoxyphenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[3-(5-phenyl-1H-1,2,4-triazol-1-yl)phenyl]piperazine;
 trans 1-[3-[2-(5-chloro-2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[2-(3-methylthio-5-pentyl-4H-1,2,4-triazol-4-yl)phenyl]piperazine;
 4-[4-[4-[2-(2,6-diethoxyphenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-phenylmethyl-3H-1,2,4-triazol-3-one;
 cis 4-[4-[4-[2-(2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-methyl-5-phenylmethyl-3H-1,2,4-triazol-3-one;


Example XXX

Following the procedure described in Example XXI there are also prepared:

- 1-[4-[2-(4-fluorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(5-methylthio-1H-tetrazol-1-yl)-phenyl]piperazine;
 trans 1-[4-[2-(5-chloro-2-thienyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-[4-(5-phenylethyl-1H-tetrazol-1-yl)phenyl]piperazine.

Claims

1. A chemical compound selected from the group consisting of an azole derivative having the formula:




and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein:

- Q is a member selected from the group consisting of CH and N;
 Ar is a member selected from the group consisting of phenyl, thienyl, halothieryl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of halo, C₁-C₈ alkyl, C₁-C₈ alkyloxy and trifluoromethyl; and
 the radical Y is a member selected from the group consisting of



40


a 1H-pyrrol-1-yl radical of the formula



(a)

wherein R¹, R², R³ and R⁴ are each independently selected from the group consisting of hydrogen, C₁—C₆ alkyl, aryl and aryl C₁—C₆ alkyl;


a 1H-pyrazol-1-yl radical of the formula



(b)

wherein R⁵, R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, C₁—C₆ alkyl, aryl and aryl C₁—C₆ alkyl;


a 1H-imidazol-1-yl radical of the formula



(c)

wherein R⁸ is selected from the group consisting of hydrogen, C₁—C₆ alkyl, mercapto, C₁—C₆ alkylthio and aryl C₁—C₆ alkylthio, and R⁹ and R¹⁰ are each independently selected from the group consisting of hydrogen, C₁—C₆ alkyl, aryl and aryl C₁—C₆ alkyl;


a 1H-1,2,4-triazol-1-yl radical of the formula



(d)

wherein either of R¹¹ and R¹² is selected from the group consisting of hydrogen, hydroxy, mercapto, C₁—C₆ alkylthio and aryl-C₁—C₆ alkylthio, the remaining being selected from the group consisting of hydrogen, C₁—C₆ alkyl and aryl-C₁—C₆ alkyl;

a 4H-1,2,4-triazol-4-yl radical of the formula




(e)

wherein R¹³ is selected from the group consisting of hydrogen, mercapto, hydroxy, C₁—C₆ alkylthio and aryl C₁—C₆ alkylthio, and R¹⁴ is selected from the group consisting of hydrogen, C₁—C₆ alkyl, aryl and aryl C₁—C₆ alkyl;



0006711


a 2,3-dihydro-4H-1,2,4-triazol-4-yl radical of the formula



(f)

wherein R¹⁵ is selected from the group consisting of C₁—C₆ alkyl and aryl C₁—C₆ alkyl and R¹⁶ is selected from the group consisting of hydrogen, C₁—C₆ alkyl, and aryl C₁—C₆ alkyl;

a 1H-1,2,3,4-tetrazol-1-yl radical of the formula



(g)

wherein R¹⁷ is selected from the group consisting of hydrogen, mercapto, C₁—C₆ alkyl, aryl and aryl C₁—C₆ alkyl;

wherein said aryl as used in the foregoing definition is selected from the group consisting of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of halo, C₁—C₆ alkyl, C₁—C₆ alkyloxy and trifluoromethyl.

2. A chemical compound selected from the group consisting of *cis* - 1 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 4 - [4 - (1H - imidazol - 1 - yl)phenyl]piperazine and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

3. A chemical compound selected from the group consisting of *cis* - 1 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 4 - [4 - (1H - 1,2,4 - triazol - 1 - yl)phenyl]piperazine and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

4. A chemical compound selected from the group consisting of *cis* - 4 - [4 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 1 - piperazinyl]phenyl] - 2,4 - dihydro - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - one and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

5. A chemical compound selected from the group consisting of *cis* - 4 - [4 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 1 - piperazinyl]phenyl] - 2,4 - dihydro - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - one monohydrate and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

6. A chemical compound selected from the group consisting of *cis* - 1 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 4 - [4 - (1H - tetrazol - 1 - yl)phenyl]piperazine and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

7. A chemical compound selected from the group consisting of *cis* - 1 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 4 - [4 - [3 - (methylthio) - 1H - 1,2,4 - triazol - 1 - yl]phenyl]piperazine and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

8. A chemical compound selected from the group consisting of *cis* - 4 - [4 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 1 - piperazinyl]phenyl] - 2 - ethyl - 2,4 - dihydro - 5 - methyl - 3H - 1,2,4 - triazol - 3 - one and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.


9. A chemical compound selected from the group consisting of *cis* - 4 - [4 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 1 - piperazinyl]phenyl] - 2,4 - dihydro - 5 - methyl - 2 - propyl - 3H - 1,2,4 - triazol - 3 - one monohydrate and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

10. A chemical compound selected from the group consisting of *cis* - 4 - [4 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 1 - piperazinyl]phenyl] - 2 - ethyl - 2,4 - dihydro - 3H - 1,2,4 - triazol - 3 - one and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

11. A composition for combatting the growth of a microorganism selected from the group consisting of fungus and bacterium comprising an inert carrier material and as an active ingredient an



effective antifungal or antibacterial amount of a compound according to any one of Claims 1 to 10.
12. A chemical compound having the formula




and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein:

Q is a member selected from the group consisting of CH and N;

Ar is a member selected from the group consisting of phenyl, thienyl, halothieryl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl.

13. A composition for combatting the growth of a microorganism selected from the group consisting of fungus and bacterium comprising an inert carrier material and as an active ingredient an effective antifungal or antibacterial amount of a compound according to Claim 12.

14. A process for preparing a chemical compound according to Claim 1 characterized by a) reacting a compound of the formula




(III)

with a compound of the formula



(II)


wherein D is



W is a reactive ester residue;

Y' is the same as Y as previously defined, but other than a radical of formula (c) or (g) wherein R⁶, respectively R¹⁷, is mercapto and other than a radical of formula (d) or (e) wherein R¹¹ or R¹², respectively R¹³, is mercapto or hydroxy;

in order to prepare a compound of the formula




(II')

the reaction being carried out in an appropriate reaction inert organic solvent, at elevated temperatures, and if desired, first converting the substituted phenol into a metal salt thereof, and to thereafter use said metal salt in the reaction with (II); or



0 006 711


b) cyclizing a compound of the formula



10 with a compound of the formula



the reaction being carried out by stirring the reactants together in the presence of an appropriate polar
15 solvent, in admixture with an appropriate water-miscible organic solvent, or
c) N-alkylating a compound of the formula




25 with a compound of the formula




said N-alkylation being carried out by stirring the reactants together, in the presence of an appropriate
base; or

30 d) cyclizing a compound of the formula




wherein A is an amino group or a suitable derivative thereof, with an appropriate cyclizing agent, and if
40 desired, introducing substituents into the thus obtained heterocyclic compounds, the nature of A in
formula (VIII), as well as the nature of the cyclizing agent to be used in the cyclization step, depending
upon the meaning of Y in the desired compounds (I),


d)(i) the compounds of formula (I) wherein Y stands for the radical (a), wherein R¹, R², R³, and R⁴
have the previously defined meaning, being derived from an appropriate amine of formula



by cyclizing the latter compound with a compound of the formula




60 or a compound of the formula






in order to prepare a compound of the formula




the reaction of (VIII-a) with (IX-a) being carried out by stirring and refluxing the reactants together in an appropriate solvent, in the presence of an appropriate base;


d)(ii) the compounds of formula (I) wherein Y stands for the radical (b), wherein R⁵, R⁶ and R⁷ have the previously defined meaning being derived from an appropriate hydrazine of the formula



by cyclizing the latter with an appropriate dione of formula




in order to prepare a compound of the formula




the reaction of (VIII-b) with (X) being carried out following the same procedure as for the preparation of (I-a) starting from (VIII-a) and (IX-a), and when R⁵ is hydrogen, the adjacent carbonyl group of (X) is preferably acetalized prior to reacting said (X) with (VIII-b) in order to obtain a pyrazole derivative wherein R⁶ is unambiguously located at the 5-position;

d)(iii) the compounds of formula (I) wherein Y stands for a radical (c) wherein R⁸ and R¹⁰ are as previously defined and wherein R⁹ stands for mercapto, being prepared by cyclizing an appropriate isothiocyanate of formula




55 with a compound of the formula





in order to prepare a compound of the formula

5




10

the reaction of (VIII-c) with (XI) being carried out by stirring the reactants together in a suitable organic solvent, in the presence of an appropriate base, the compounds of formula (I) wherein Y stands for the radical (c) wherein R⁹ and R¹⁰ are as previously defined and wherein R⁸ stands for hydrogen, being obtained by desulfurating a compound of formula (I-c-1) in order to prepare a compound of the formula

15


20



the compounds of formula (I) wherein Y represents the radical (c) wherein R⁹ and R¹⁰ are as previously described and wherein R⁸ is C₁-C₆ alkylthio or aryl-C₁-C₆ alkylthio, being prepared by subjecting the corresponding compounds of formula (I-c-1) to a standard S-alkylation with a suitable reactive ester of the formula R^a_sW (XII), wherein R^a_s is C₁-C₆ alkyl or aryl-C₁-C₆ alkyl and wherein W is as previously defined, in order to prepare a compound of the formula

25

30




35

and, if desired, the compounds of formula (I-c-3) may be desulfurated yielding the compounds of formula (I-c-2); or

40

e) preparing compounds of formula (I) wherein Y is the radical (d), wherein R¹¹ represents XH, X being O or S, and wherein R¹² is hydrogen, C₁-C₆ alkyl or aryl-C₁-C₆ alkyl, said R¹² being represented by R^{12a} by cyclizing a compound of the formula

45




50

with



or a functional derivative thereof, the resultant product being a compound of the formula

60



65



47

said reaction being conveniently carried out by stirring and heating the reactants together in an appropriate organic solvent; or


e)(i) the compounds of formula (I-d-1) may alternatively be prepared by first acylating (VIII-d-1) with an appropriate anhydride of the formula



or an alkanolic halide of the formula



in order to prepare a compound of the formula




and, subsequently, cyclizing the latter by stirring and heating (XIV) in an alcoholic alkaline medium; or

e)(ii) preparing the compounds of formula (I-d-1) by reacting a hydrazine hydrochloride of formula (VIII-b) with a compound of formula




in N,N-diethylethanamine, washing the reaction mixture with water, evaporating off the solvent and thereafter stirring and heating the residue in a mixture of dichloromethane and ethanol in the presence of alkali; or

e)(iii) preparing the compounds of formula (I) wherein Y stands for the radical (d) wherein R^{12} is R^{12}_a and wherein R^{11} is hydrogen by desulfurating a corresponding compound of formula (I-d-1), wherein XH is SH, said compounds being represented by the formula




following the same procedure as for the desulfuration of (I-c-1) to prepare (I-c-2), the product being a compound of the formula



e)(iv) preparing compounds of formula (I) wherein Y stands for the radical (d) wherein R^{12} is R^{12}_a and wherein R^{11} is C_1-C_8 alkylthio or aryl- C_1-C_8 alkylthio, by S-alkylating a compound of formula (I-d-1-a) with a reactive ester of formula R^{11}_aW (XV-a), wherein W has the previously defined meaning and wherein R^{11} stands for C_1-C_8 alkyl or aryl- C_1-C_8 alkyl, following the same procedure as for the




preparation of (I-c-3) starting from (I-c-1) and (XII), the product being a compound of the formula



15 and, if desired, following the same desulfurating procedure as described hereinabove, the compounds of formula (I-d-3) may be converted into the compounds of formula (I-d-2); or


e)(v) preparing compounds of formula (I) wherein Y stands for the radical (d) wherein R¹² is XH, X being O or S, and wherein R¹¹ is hydrogen, C₁—C₆ alkyl or aryl-C₁—C₆ alkyl, said R¹¹ being represented by R^{11b}, by cyclizing a compound of the formula



with a compound of the formula




or a functional derivative thereof, the product being a compound of the formula




or

e)(vi) preparing compounds of formula (I) wherein Y represents the radical (d) wherein R¹² is hydrogen and wherein R¹¹ has the meaning of R^{11b}, by desulfurating a compound of formula






the product being a compound of the formula




e)(vii) preparing compounds of formula (I) wherein Y represents the radical (d) wherein R^{12} is C_1-C_6 alkylthio or aryl- C_1-C_6 alkylthio and wherein R^{11} has the meaning of R^{11}_b , by S-alkylating a compound of formula (I-d-4-a) with a reactive ester of formula R^{12}_bW (XV-b), wherein W is as previously described and wherein R^{12}_b is C_1-C_6 alkyl or aryl- C_1-C_6 alkyl, following the previously described procedure for the preparation of (I-c-3) starting from (I-c-1) and (XII), the product being a compound of the formula



and following the desulfurating procedure described hereinabove, the compounds of formula (I-d-6) may in turn be converted into the compounds of formula (I-d-5); or


f) preparing compounds of formula (I) wherein Y stands for a radical of formula (e) wherein R^{14} has the previously defined meaning and wherein R^{13} stands for mercapto or hydroxy, said R^{13} being represented by XH , wherein X is O or S, by cyclizing a compound of the formula



with a compound of formula



or an acid addition salt thereof, the product being a compound of the formula




f)(i) preparing compounds of formula (I) wherein Y stands for the radical (e) wherein R^{14} is as previously defined and wherein R^{13} stands for C_1-C_6 alkylthio or aryl- C_1-C_6 alkylthio, said R^{13} being




0006711

represented by SR^{13}_a , wherein R^{13}_a is C_1-C_6 alkyl or aryl- C_1-C_6 alkyl, by S-alkylating a compound of formula




with a compound of the formula R^{13}_aW (XVII)

the product being a compound of the formula




and if desired, compounds of formula (I) wherein Y stands for the radical (e) wherein R^{14} is as previously defined and wherein R^{13} stands for hydrogen, can be prepared by desulfurating a corresponding compound of formula (I-e-1-a) or a compound of formula (I-e-3), following standard desulfuration reactions as previously described herein, the product being a compound of the formula




or

g) preparing compounds of formula (I) wherein Y represents a radical (f) wherein R^{15} and R^{16} have the previously defined meaning, can be derived from an appropriate compound of formula



by N-alkylating the latter with an appropriate reactive ester of formula $R^{15}W$ (XVIII), wherein W and R^{15} have the previously defined meanings, the product being a compound of the formula




h) preparing compounds of formula (I) wherein Y stands for the radical (g) wherein R^{17} is as previously defined, but other than mercapto, said R^{17} being represented by R^{17}_a , by cyclizing a compound of the formula (VIII-a) with an azide and a compound of the formula






in an appropriate acidic medium, the product being a compound of the formula




10 or

h)(i) preparing compounds of formula (I), wherein Y stands for the radical (g) wherein R¹⁷ stands for mercapto, by cyclizing an isothiocyanate of formula (VIII-c) with an appropriate azide, in an appropriate organic solvent, in the presence of alkali, the product being a compound of the formula



or the cyclization reaction may also be carried out by stirring (VIII-c) with an azide in the presence of an appropriate quaternary ammonium salt, in a suitable solvent system;

or h)(ii) preparing compounds of formula (I-g) wherein R¹⁷ is hydrogen by desulfurating a compound of formula (I-g-2), the product being a compound of the formula



and, if desired, preparing pharmaceutically acceptable acid addition salts of the products of the above steps, and also, if desired, preparing stereochemical isomeric forms of compound (I).

40 15. A process for preparing a chemical compound selected from the group consisting of *cis* - 1 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 4 - [4 - (1H - imidazol - 1 - yl)phenyl] - piperazine and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, characterized by reacting 4 - [4 - (1H - imidazol - 1 - yl)phenyl] - 1 - piperazinylphenol with *cis* - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethyl]methanesulfonate.

45 16. A process for preparing a chemical compound selected from the group consisting of *cis* - 1 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 1 - ylmethoxy] - phenyl] - 4 - [4 - (1H - 1,2,4 - triazol - 1 - yl) - phenyl]piperazine and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, characterized by reacting 4 - [4 - (1H - 1,2,4 - triazol - 1 - yl)phenyl] - 1 - piperazinylphenol with *cis* - [2 - (2,4 - dichlorophenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethyl]methanesulfonate.

50 17. A process for preparing a chemical compound selected from the group consisting of *cis* - 4 - [4 - [4 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - imidazol - 1 - yl - methyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 1 - piperazinyl]phenyl] - 2,4 - dihydro - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - one and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, characterized by reacting 2,4 - dihydro - 4 - [4 - [4 - (4 - hydroxyphenyl) - 1 - piperazinyl] - phenyl] - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - one with *cis* - [2 - (2,4 - dichlorophenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethyl]methanesulfonate.

55 18. A process for preparing a chemical compound selected from the group consisting of *cis* - 4 - [4 - [4 - [4 - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 1 - piperazinyl]phenyl] - 2,4 - dihydro - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - one monohydrate and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, characterized by reacting 2,4 - dihydro - 4 - [4 - [4 - (4 - hydroxyphenyl) - 1 - piperazinyl]phenyl] - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - one with *cis* - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethyl]methanesulfonate.



0006711


19. A process for preparing a compound of the formula *cis* - 1 - [4 - [2 - (2,4 - dichlorophenyl)-2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]phenyl] - 4 - [4 - (5 - methyl - 1H - 1,2,4 - triazol - 1 - yl)phenyl]piperazine, characterized by reacting 4 - [4 - (5 - methyl - 1H - 1,2,4 - triazol - 1 - yl)phenyl] - 1 - piperazinylphenol with *cis* - [2 - (2,4 - dichlorophenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethyl]methanesulfonate.

20. A process for preparing a chemical compound according to Claim 12 characterized by reacting a compound (II) of the formula




(II)

wherein D is



and W is a reactive ester residue, with a compound of the formula




in an appropriate reaction inert organic solvent, at elevated temperatures, or if desired, first converting the substituted phenol into a metal salt thereof, and to thereafter use said metal salt in the reaction with (II).

21. A compound according to any one of Claims 1 to 10 or Claim 12, or a composition according to Claim 11 or Claim 13, for use in combatting the growth of a fungus or bacterium.

22. A process for preparing a pharmaceutical composition comprising mixing an effective amount of a compound claimed in any one of Claims 1 to 10 or 12 with an inert carrier material.

Patentansprüche

1. Eine chemische Verbindung, ausgewählt aus der ein Azolderivat mit der Formel:



und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemischen isomeren Formen hiervon umfassenden Gruppe, worin:

Q ein Vertreter aus der CH und N umfassenden Gruppe ist;


Ar ein Vertreter aus der Gruppe ist, die aus Phenyl, Thienyl, Halogenthienyl und substituiertem Phenyl besteht, wobei das genannte substituierte Phenyl 1 bis 3 Substituenten aufweist, die jeweils unabhängig voneinander ausgewählt sind aus einer Halogen, C₁-C₆-Alkyl, C₁-C₆-Alkyloxy und Tri-fluormethyl umfassenden Gruppe; und

der Rest Y ein Vertreter aus einer Gruppe ist, die besteht aus:



53


einem 1H-Pyrrrol-1-yl-Rest der Formel



(a)

10 worin R^1 , R^2 , R^3 und R^4 jeweils unabhängig voneinander ausgewählt sind aus einer Wasserstoff, C_1-C_6 -Alkyl, Aryl und Aryl- C_1-C_6 -alkyl umfassenden Gruppe;


einem 1H-Pyrazol-1-yl-Rest der Formel



(b)

20 worin R^5 , R^6 und R^7 jeweils unabhängig voneinander ausgewählt sind aus einer Wasserstoff, C_1-C_6 -Alkyl, Aryl und Aryl- C_1-C_6 -alkyl umfassenden Gruppe;


einem 1H-Imidazol-1-yl-Rest der Formel



(c)

30 worin R^8 ausgewählt ist aus einer Wasserstoff, C_1-C_6 -Alkyl, Mercapto, C_1-C_6 -Alkylthio und Aryl- C_1-C_6 -alkylthio umfassenden Gruppe und R^9 und R^{10} jeweils unabhängig voneinander ausgewählt sind aus einer Wasserstoff, C_1-C_6 -Alkyl, Aryl und Aryl- C_1-C_6 -alkyl umfassenden Gruppe;


40 einem 1H-1,2,4-Triazol-1-yl-Rest der Formel



(d)

45 worin entweder R^{11} oder R^{12} ausgewählt ist aus einer Wasserstoff, Hydroxy, Mercapto, C_1-C_6 -Alkylthio und Aryl- C_1-C_6 -alkylthio umfassenden Gruppe, während der andere Rest ausgewählt ist aus einer Wasserstoff, C_1-C_6 -Alkyl und Aryl- C_1-C_6 -alkyl umfassenden Gruppe;

einem 4H-1,2,4-Triazol-4-yl-Rest der Formel




(e)

60 worin R^{13} ausgewählt ist aus einer Wasserstoff, Mercapto, Hydroxy, C_1-C_6 -Alkylthio und Aryl- C_1-C_6 -alkylthio umfassenden Gruppe und R^{14} ausgewählt ist aus einer Wasserstoff, C_1-C_6 -Alkyl, Aryl und Aryl- C_1-C_6 -alkyl umfassenden Gruppe;




0 006 711

5 einem 2,3-Dihydro-4H-1,2,4-triazol-4-yl-Rest der Formel



15 worin R¹⁵ ausgewählt ist aus der C₁-C₆-Alkyl und Aryl-C₁-C₆-alkyl umfassenden Gruppe und R¹⁶ ausgewählt ist aus der Wasserstoff, C₁-C₆-Alkyl und Aryl-C₁-C₆-alkyl umfassenden Gruppe;

20 einem 1H-1,2,3,4-Tetrazol-1-yl-Rest der Formel



30 worin R¹⁷ ausgewählt ist aus der Wasserstoff, Mercapto, C₁-C₆-Alkyl, Aryl und Aryl-C₁-C₆-alkyl umfassenden Gruppe; worin das genannte Aryl, wie es in den obigen Definitionen verwendet wird, ausgewählt ist aus der Phenyl und substituiertes Phenyl umfassenden Gruppe, wobei das genannte substituierte Phenyl 1 bis 3 Substituenten aufweist, die jeweils unabhängig voneinander ausgewählt sind aus der Halogen, C₁-C₆-Alkyl, C₁-C₆-Alkyloxy und Trifluormethyl umfassenden Gruppe.

35 2. Eine chemische Verbindung, ausgewählt aus der cis - 1 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 4 - [4 - (1H - imidazol - 1 - yl) - phenyl] - piperazin und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hiervon umfassenden Gruppe.

40 3. Eine chemische Verbindung, aus der cis - 1 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 4 - [4 - (1H - 1,2,4 - triazol - 1 - yl) - phenyl] - piperazin und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hiervon umfassenden Gruppe.

45 4. Eine chemische Verbindung, ausgewählt aus der cis - 4 [4 - [4 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 1 - piperazinyl]phenyl] - 2,4 - dihydro - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - on und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hiervon umfassenden Gruppe.

50 5. Eine chemische Verbindung, ausgewählt aus der cis - 4 - [4 - [4 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 1 - piperazinyl]phenyl] - 2,4 - dihydro - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - on - Monohydrat und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hiervon umfassenden Gruppe.

55 6. Eine chemische Verbindung, ausgewählt aus der cis - 1 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 4 - [4 - (1H - tetrazol - 1 - yl) - phenyl] - piperazin und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hiervon umfassenden Gruppe.

60 7. Eine chemische Verbindung, ausgewählt aus der cis - 1 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 4 - [4 - [3 - methylthio] - 1H - 1,2,4 - triazol - 1 - yl] - phenyl] - piperazin und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hiervon umfassenden Gruppe.

65 8. Eine chemische Verbindung, ausgewählt aus der cis - 4 - [4 - [4 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 1 - piperazinyl]phenyl] - 2 - ethyl - 2,4 - dihydro - 5 - methyl - 3H - 1,2,4 - triazol - 3 - on und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hiervon umfassenden Gruppe.

9. Eine chemische Verbindung, ausgewählt aus der cis - 4 - [4 - [4 - [4 - [2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 1 - piperazinyl]phenyl] - 2,4 - dihydro - 5 - methyl - 2 - propyl - 3H - 1,2,4 - triazol - 3 - on - Monohydrat und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hiervon umfassenden Gruppe.


10. Eine chemische Verbindung, ausgewählt aus der cis - 4 - [4 - [4 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 1 - piperazinyl]phenyl] - 2 - ethyl - 2,4 - dihydro - 3H - 1,2,4 - triazol - 3 - on und die pharmazeutisch



annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hievon umfassenden Gruppe.

11. Eine Zusammensetzung zur Bekämpfung des Wachstums eines Mikroorganismus, ausgewählt aus der aus Fungus und Bacterium bestehenden Gruppe, umfassend ein inertes Trägermaterial und als einen wirksamen Bestandteil eine antifungal oder antibakteriell wirksame Menge einer Verbindung gemäß einem der Ansprüche 1 bis 10.

12. Eine chemische Verbindung mit der Formel



und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hievon, worin:


Q ein Vertreter aus der CH und N umfassenden Gruppe ist;

Ar ein Vertreter aus der Gruppe ist, die aus Phenyl, Thienyl, Halogenthienyl und substituiertem Phenyl besteht, wobei das genannte substituierte Phenyl 1 bis 3 Substituenten aufweist, die jeweils unabhängig voneinander ausgewählt sind aus einer Halogen, Niederalkyl, Niederalkyloxy und Trifluor-methyl umfassenden Gruppe.

13. Eine Zusammensetzung zur Bekämpfung des Wachstums eines Mikroorganismus, ausgewählt aus der Gruppe bestehend aus Fungus and Bacterium, umfassend ein inertes Trägermaterial und als einen aktiven Bestandteil eine antifungal oder antibakteriell wirksame Menge einer Verbindung gemäß Anspruch 12.

14. Ein Verfahren zur Herstellung einer chemischen Verbindung nach Anspruch 1, gekennzeichnet durch

a) Umsetzen einer Verbindung der Formel




(III)

mit einer Verbindung der Formel




(II)

worin D für



steht und W einen reaktionsfähigen Esterrest bedeutet; worin Y' wie zuvor Y definiert ist, jedoch eine andere Bedeutung als einen Rest der Formel (c) oder (g) hat, worin R⁸ bzw. R¹⁷ Mercapto ist, und eine andere Bedeutung als einen Rest der Formel (d) oder (e) hat, worin R¹¹ oder R¹² bzw. R¹³ Mercapto oder Hydroxy ist;

zur Herstellung einer Verbindung der Formel




(I')



0006711

wobei die Umsetzung in einem geeigneten reaktionsinerten organischen Lösungsmittel bei erhöhter Temperatur ausgeführt wird und wobei gewünschtenfalls das substituierte Phenol (III) zunächst in ein Metallsalz hievon übergeführt und hiernach dieses Metallsalz in der Reaktion mit (II) eingesetzt wird; oder

5 b) Cyclisieren einer Verbindung der Formel



15 mit einer Verbindung der Formel




wobei die Umsetzung durch gemeinsames Rühren der Reaktionskomponenten in Gegenwart eines geeigneten polaren Lösungsmittels, im Gemisch mit einem geeigneten wassermischbaren organischen Lösungsmittel, ausgeführt wird; oder

20 c) N-Alkylierung einer Verbindung der Formel




mit einer Verbindung der Formel




wobei die N-Alkylierung durch gemeinsames Rühren der Reaktionskomponenten in Gegenwart einer geeigneten Base ausgeführt wird; oder

35 d) Cyclisierung einer Verbindung der Formel




45 worin A eine Aminogruppe oder ein geeignetes Derivat hievon darstellt, mit einem entsprechenden Cyclisierungsmittel und, falls gewünscht, Einführung von Substituenten in die solcherart erhaltenen heterocyclischen Verbindungen, wobei die Art von A in Formel (VIII) sowie die Art des in der Cyclisierungsstufe zu verwendenden Cyclisierungsmittels von der Bedeutung von Y in den erwünschten Verbindungen (I) abhängen, wobei

50 d)(i) die Verbindungen der Formel (I), worin Y für den Rest (a) steht, worin R¹, R², R³ und R⁴ die vorstehend definierte Bedeutung haben, von einem entsprechenden Amin der Formel




60 durch Cyclisieren der letztgenannten Verbindung mit einer Verbindung der Formel






0 006 711

oder einer Verbindung der Formel



(IX-b)


unter Ausbildung einer Verbindung der Formel



(I-a)


abgeleitet werden, worin die Umsetzung von (VIII-a) mit (IX-a) durch gemeinsames Rühren und Rückflußerhitzen der Komponenten in einem entsprechenden Lösungsmittel in Gegenwart einer entsprechenden Base ausgeführt wird;

d)(ii) die Verbindungen der Formel (I), worin Y für den Rest (b) steht, worin R⁵, R⁶ und R⁷ die zuvor angegebene Bedeutung haben, von einem entsprechenden Hydrazin der Formel




(VIII-b)

durch Cyclisieren der letztgenannten Verbindung mit einem entsprechenden Dione der Formel



(X)


unter Ausbildung einer Verbindung der Formel



(I-b)

abgeleitet werden, worin die Umsetzung von (VIII-b) mit (X) nach der gleichen Vorgangsweise erfolgt wie die Herstellung von (I-a) aus (VIII-a) und (IX-a), und, falls R⁵ für Wasserstoff steht, die benachbarte Carbonylgruppe vorzugsweise vor der Umsetzung der genannten Verbindung (X) mit der Verbindung (VIII-b) acetalisiert wird, um ein Pyrazolderivat zu erhalten, worin R⁶ unzweideutig an der 5-Stellung lokalisiert ist;

d)(iii) die Verbindungen der Formel (I), worin Y für einen Rest (c) steht, worin R⁸ und R¹⁰ wie zuvor definiert sind und worin R⁹ für Mercapto steht, durch Cyclisieren eines entsprechenden Isothiocyanats der Formel




(VIII-c)




88

mit einer Verbindung der Formel




(XI)

unter Ausbildung einer Verbindung der Formel



(I-c-1)

hergestellt werden, wobei die Umsetzung von (VIII-c) mit (XI) durch gemeinsames Rühren der Reaktanten in einem geeigneten organischen Lösungsmittel in Gegenwart einer entsprechenden Base ausgeführt wird, wobei die Verbindungen der Formel (I), worin Y für den Rest (c) steht, worin R^9 und R^{10} wie zuvor definiert sind und worin R^8 für Wasserstoff steht, durch Desulfurieren einer Verbindung der Formel (I-c-1) unter Ausbildung einer Verbindung der Formel




(I-c-2)

hergestellt werden, wobei die Verbindungen der Formel (I), worin Y den Rest (c) darstellt, worin R^9 und R^{10} wie zuvor definiert sind und worin R^8 für C_1-C_6 -Alkylthio oder Aryl- C_1-C_6 -alkylthio steht, durch eine übliche S-Alkylierung der entsprechenden Verbindungen der Formel (I-c-1) mit einem geeigneten reaktionsfähigen Ester der Formel



(XII)


worin R^8_a für C_1-C_6 -Alkyl oder Aryl- C_1-C_6 -alkyl steht und worin W wie zuvor definiert ist, unter Ausbildung einer Verbindung der Formel



(I-c-3)


dargestellt werden, und, gewünschtenfalls, die Verbindungen der Formel (I-c-3) unter Ausbildung von Verbindungen der Formel (I-c-2) desulfuriert werden; oder

e) Verbindungen der Formel (I), worin Y für den Rest (d) steht, worin R^{11} für XH steht, wobei X für O oder S steht, und worin R^{12} Wasserstoff, C_1-C_6 -Alkyl oder Aryl- C_1-C_6 -alkyl bedeutet, welcher Rest R^{12} durch R^{12}_a dargestellt wird, durch Cyclisieren einer Verbindung der Formel



(VIII-d-1)


mit



(XIII)



oder einem funktionellen Derivat hiervon hergestellt werden, wobei das erhaltene Produkt eine Verbindung der Formel



15 ist, welche Umsetzung zweckmäßig durch gemeinsames Rühren und Erhitzen der Reaktionskomponenten in einen entsprechenden organischen Lösungsmittel ausgeführt wird; oder


e)(i) die Verbindungen der Formel (I-d-1) in alternativer Weise dadurch hergestellt werden können, daß zunächst (VIII-d-1) mit einem entsprechenden Anhydrid der Formel



20 oder einem Alkanoylhalogenid der Formel



25 unter Ausbildung einer Verbindung der Formel




acyliert und anschließend das letztgenannte durch Rühren und Erhitzen von (XIV) in einem alkoholischen alkalischen Medium cyclisiert wird; oder

40 e)(ii) Verbindungen der Formel (I-d-1) durch Umsetzung eines Hydrazinhydrochlorids der Formel (VIII-b) mit einer Verbindung der Formel



in N,N-Diethylethanamin, Waschen des Reaktionsgemisches mit Wasser, Abdampfen des Lösungsmittels und anschließendes Rühren und Erhitzen des Rückstandes in einem Gemisch aus Dichlormethan und Ethanol in Gegenwart von Alkali hergestellt werden; oder

50 e)(iii) die Verbindungen der Formel (I), worin Y für den Rest (d) steht, worin R¹² als R¹²_a vorliegt und worin R¹¹ Wasserstoff bedeutet, durch Desulfurieren einer entsprechenden Verbindung der Formel (I-d-1) hergestellt werden, worin XH für SH steht, welche Verbindungen durch die Formel




(XIII)

65 dargestellt werden, wobei die gleiche Vorgangsweise wie für die Desulfurierung von (I-c-1) zur



0006711

Herstellung von (I-c-2) eingehalten wird, wobei das Produkt eine Verbindung der Formel



10 ist; oder

e)(iv) Verbindungen der Formel (I), worin Y für den Rest (d) steht, worin R^{12} als R^{12}_a vorliegt und worin R^{11} C_1-C_8 -Alkylthio oder Aryl- C_1-C_8 -alkylthio bedeutet, durch S-Alkylierung einer Verbindung der Formel (I-d-1-a) mit einem reaktiven Ester der Formel


15



(XV-a)

hergestellt werden; worin W die zuvor angegebene Bedeutung hat und worin R^{11}_a für C_1-C_8 -Alkyl oder Aryl- C_1-C_8 -alkyl steht, wobei die gleiche Vorgangsweise wie für die Herstellung von (I-c-3) aus (I-c-1) und (XII) eingehalten wird, wobei das Produkt eine Verbindung der Formel

20




30

ist, und, gewünschtenfalls, nach der gleichen Desulfurierungsmethode wie zuvor beschrieben, die Verbindungen der Formel (I-d-3) in die Verbindungen der Formel (I-d-2) übergeführt werden können; oder

e)(v) Verbindungen der Formel (I), worin Y für den Rest (d) steht, worin R^{12} für XH steht, wobei X für O oder S steht und worin R^{11} Wasserstoff, C_1-C_8 -Alkyl oder Aryl- C_1-C_8 -alkyl bedeutet, welcher Rest R^{11} durch das Symbol R^{11}_b veranschaulicht wird, durch Cyclisierung einer Verbindung der Formel


35



45

mit einer Verbindung der Formel


50



(XIII-d)

oder einem funktionellen Derivat hiervon unter Ausbildung einer Verbindung der Formel

55



hergestellt werden; oder


65

e)(vi) Verbindungen der Formel (I), worin Y den Rest (d) darstellt, worin R^{12} Wasserstoff bedeutet




0 006 711

und worin R^{11} die Bedeutung von R^{11}_b aufweist, durch Desulfurierung einer Verbindung der Formel



unter Ausbildung eines Produktes der Formel




25 hergestellt werden; oder

e)(vii) Verbindungen der Formel (I), worin Y den Rest (d) bedeutet, worin R^{12} für C_1-C_6 -Alkylthio oder Aryl- C_1-C_6 -alkylthio steht und worin R^{11} die Bedeutung von R^{11}_b aufweist, durch S-Alkylierung einer Verbindung der Formel (1-d-4-a) mit einem reaktiven Ester der Formel




hergestellt werden, worin W wie zuvor beschrieben ist und worin R^{12}_b für C_1-C_6 -Alkyl oder Aryl- C_1-C_6 -alkyl steht, wobei die zuvor für die Herstellung von (1-c-3) aus (1-c-1) und (XII) beschriebenen Methode eingehalten wird, wobei das Produkt eine Verbindung der Formel




45 ist, und wobei nach der vorbeschriebenen Desulfurierungsmethode die Verbindungen der Formel (1-d-6) ihrerseits in die Verbindungen der Formel (1-d-5) übergeführt werden können; oder

f) Herstellung von Verbindungen der Formel (I), worin Y für einen Rest der Formel (e) steht, worin R^{14} die zuvor angegebene Bedeutung hat und worin R^{13} für Mercapto oder Hydroxy steht, welcher Rest R^{13} durch XH dargestellt wird, worin X für O oder S steht, durch Cyclisierung einer Verbindung der Formel




mit einer Verbindung der Formel






oder einem Säureadditionssalze hiervon, wobei das Produkt eine Verbindung der Formel



ist; oder


f)(i) Herstellung von Verbindungen der Formel (I), worin Y für den Rest (e) steht, worin R¹⁴ wie zuvor definiert ist und worin R¹³ für C₁—C₆-Alkylthio oder Aryl-C₁—C₆-alkylthio steht, welcher Rest R¹³ durch das Symbol SR¹³_a dargestellt wird, worin R¹³ C₁—C₆-Alkyl oder Aryl-C₁—C₆-alkyl bedeutet, durch S-Alkylierung einer Verbindung der Formel




mit einer Verbindung der Formel R¹³_aW

(XVII)

wobei das Produkt eine Verbindung der Formel




40 ist und, gewünschtenfalls, Verbindungen der Formel (I), worin Y für den Rest (e) steht, worin R¹⁴ wie zuvor definiert ist und worin R¹³ für Wasserstoff steht, durch Desulfurierung einer entsprechenden Verbindung der Formel (I-e-1-a) oder einer Verbindung der Formel (I-e-3) erhalten werden können, wobei Standard-Desulfurierungsreaktionen, wie zuvor hierin beschrieben, angewendet werden, wobei das Produkt eine Verbindung der Formel



ist; oder

g) Herstellung von Verbindungen der Formel (I), worin Y einen Rest (f) darstellt, worin R¹⁵ und R¹⁶ die zuvor angegebene Bedeutung haben, durch N-Alkylierung einer entsprechenden Verbindung der Formel






mit einem entsprechenden reaktiven Ester der Formel

$R^{15}W$

(XVIII)

- 5 worin W und R^{15} die zuvor angegebene Bedeutung besitzen, wobei das Produkt eine Verbindung der Formel




15 ist; oder

h) Herstellung von Verbindungen der Formel (I), worin Y für den Rest (g) steht, worin R^{17} wie zuvor definiert ist, jedoch eine von Mercapto unterschiedliche Bedeutung hat, welcher Rest R^{17} durch das Symbol R^{17}_a dargestellt wird, durch Cyclisierung einer Verbindung der Formel (VIII-a) mit einem Azid und einer Verbindung der Formel




in einem entsprechenden sauren Medium, wobei das Produkt eine Verbindung der Formel




ist; oder

h)(i) Herstellung von Verbindungen der Formel (I), worin Y für den Rest (g) steht, worin R^{17} Mercapto bedeutet, durch Cyclisierung eines Isothiocyanats der Formel (VIII-c) mit einem entsprechenden Azid in einem entsprechenden organischen Lösungsmittel in Gegenwart von Alkali, wobei das Produkt eine Verbindung der Formel



ist, wobei die Cyclisierungsreaktion auch durch Rühren von (VIII-c) mit einem Azid in Gegenwart eines entsprechenden quaternären Ammoniumsalzes ausgeführt werden kann; oder

h)(ii) Herstellung von Verbindungen der Formel (I-g), worin R^{17} für Wasserstoff steht, durch Desulfurierung einer Verbindung der Formel (I-g-2), wobei das Produkt eine Verbindung der Formel



ist, und

60 gewünschtenfalls Herstellung von pharmazeutisch annehmbaren Säureadditionssalzen der Produkte der vorstehenden Stufen und gleichfalls gewünschtenfalls Herstellung stereochemisch isomerer Formen der Verbindung (I).

15. Ein Verfahren zur Herstellung einer chemischen Verbindung, ausgewählt aus der cis - 1-[4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy]-phenyl] - 4 - [4 - (1H - imidazol - 1 - yl) - phenyl] - piperazin und die pharmazeutisch annehmbaren

65



0006711

Säureadditionssalze und stereochemisch isomeren Formen hievon umfassenden Gruppe, gekennzeichnet durch Umsetzung von 4 - [4 - [4 - (1H - Imidazol - 1 - yl) - phenyl] - 1 - piperazinyl] - phenol mit cis - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethyl] - methansulfonat.

- 5 16. Ein Verfahren zur Herstellung einer chemischen Verbindung, ausgewählt aus der cis - 1 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 4 - [4 - (1H - 1,2,4 - triazol - 1 - yl) - phenyl] - piperazin und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hievon umfassenden Gruppe, gekennzeichnet durch Umsetzung von 4 - [4 - [4 - (1H - 1,2,4 - Triazol - 1 - yl) - phenyl] - 1 - piperazinyl] phenol mit cis - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethyl] - methansulfonat.

17. Ein Verfahren zur Herstellung einer chemischen Verbindung, ausgewählt aus der cis - 4 - [4 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 1 - piperazinyl] - phenyl] - 2,4 - dihydro - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - on und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hievon umfassenden Gruppe, gekennzeichnet durch Umsetzung von 2,4 - Dihydro - 4 - [4 - [4 - (4 - hydroxyphenyl) - 1 - piperazinyl] - phenyl] - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - on mit cis - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - imidazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethyl] - methansulfonat.

18. Ein Verfahren zur Herstellung einer chemischen Verbindung, ausgewählt aus der cis - 4 - [4 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 1 - piperazinyl] - phenyl] - 2,4 - dihydro - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - on - Monohydrat und die pharmazeutisch annehmbaren Säureadditionssalze und stereochemisch isomeren Formen hievon umfassenden Gruppe, gekennzeichnet durch Umsetzung von 2,4 - Dihydro - 4 - [4 - [4 - (4 - hydroxyphenyl) - 1 - piperazinyl] - phenyl] - 2,5 - dimethyl - 3H - 1,2,4 - triazol - 3 - on mit cis - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethyl] - methansulfonat.


19. Ein Verfahren zur Herstellung einer Verbindung mit der Formel cis - 1 - [4 - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethoxy] - phenyl] - 4 - [4 - (5 - methyl - 1H - 1,2,4 - triazol - 1 - yl) - phenyl] - piperazin, gekennzeichnet durch Umsetzung von 4 - [4 - [4 - (5 - Methyl - 1H - 1,2,4 - triazol - 1 - yl) - phenyl] - 1 - piperazinyl] - phenol mit cis - [2 - (2,4 - Dichlorphenyl) - 2 - (1H - 1,2,4 - triazol - 1 - ylmethyl) - 1,3 - dioxolan - 4 - ylmethyl] - methansulfonat.

20. Ein Verfahren zur Herstellung einer chemischen Verbindung gemäß Anspruch 12, gekennzeichnet durch Umsetzung einer Verbindung (II) mit der Formel




(II)

worin D für



- steht und W ein reaktionsfähiger Esterrest ist, mit einer Verbindung der Formel



in einem entsprechenden reaktionsinerten organischen Lösungsmittel bei erhöhten Temperaturen oder, gewünschtenfalls, durch vorangehende Überführung des substituierten Phenols in ein Metallsalz hievon und anschließende Verwendung dieses Metallsalzes in der Umsetzung mit (II).


21. Eine Verbindung gemäß einem der Ansprüche 1 bis 10 oder 12, oder eine Zusammensetzung gemäß Anspruch 11 oder 13, zur Verwendung in der Bekämpfung des Wachstums eines Fungus oder eines Bakteriums.

22. Ein Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, umfassend das Vermischen einer wirksamen Menge einer Verbindung gemäß einem der Ansprüche 1 bis 10 oder 12 mit einem inerten Trägermaterial.



Revendications

1. Un composé chimique choisi parmi le groupe constitué par un dérivé d'azole ayant pour formule:




et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques, où:

Q est un élément choisi dans le groupe constitué par CH et N;

Ar est un élément choisi dans le groupe constitué par phényle, thiényle, halogénothiényle et phényle substitué, ledit phényle substitué ayant 1 à 3 substituants choisis chacun indépendamment dans le groupe constitué par halogéno, alkyle en C_1-C_6 , alcoxy en C_1-C_6 et trifluorométhyle; et le radical Y est un élément choisi parmi le groupe constitué par


un radical 1H-pyrrol-1-yle de formule



(a)

où R^1 , R^2 , R^3 et R^4 sont chacun choisis indépendamment parmi le groupe constitué par un hydrogène, un alkyle en C_1-C_6 , un aryle et un aryl-alkyle en C_1-C_6 ;


un radical 1H-imidazol-1-yle de formule



(b)

où R^5 , R^6 et R^7 sont choisis chacun indépendamment parmi le groupe constitué par un hydrogène, un alkyle en C_1-C_6 , un aryle et un aryl-alkyle en C_1-C_6 ;

un radical 1H-imidazol-1-yle de formule:




(c)

où R^8 est choisi parmi le groupe constitué par un hydrogène, un alkyle en C_1-C_6 , un mercapto, un alkylthio en C_1-C_6 et un aryl-alkylthio en C_1-C_6 et R^9 et R^{10} sont choisis chacun indépendamment parmi le groupe constitué par un hydrogène, un alkyle en C_1-C_6 , un aryle et un aryl-alkyle en C_1-C_6 ;



0006711


un radical 1H-1,2,4-triazol-1-yle de formule



(d)

où l'un de R^{11} et R^{12} est choisi parmi le groupe constitué par un hydrogène, un hydroxy, un mercapto, un alkylthio en C_1-C_6 et un aryl-alkylthio en C_1-C_6 , l'autre étant choisi parmi le groupe constitué par un hydrogène, un alkyle en C_1-C_6 et un aryl-alkyle en C_1-C_6 ;


un radical 4H-1,2,4-triazol-4-yle de formule



(e)

où R^{13} est choisi parmi le groupe constitué par un hydrogène, un mercapto, un hydroxy, un alkylthio en C_1-C_6 et un aryl-alkylthio en C_1-C_6 , et R^{14} est choisi parmi le groupe constitué par un hydrogène, un alkyle en C_1-C_6 , un aryle et un aryl-alkyle en C_1-C_6 ;


un radical 2,3-dihydro-4H-1,2,4-triazol-4-yle de formule



(f)

où R^{15} est choisi parmi le groupe constitué par un alkyle en C_1-C_6 et un arylalkyle en C_1-C_6 et R^{16} est choisi parmi le groupe constitué par un hydrogène, un alkyle en C_1-C_6 et un aryl-alkyle en C_1-C_6 ;

un radical 1H-1,2,3,4-tétrazol-1-yle de formule



(g)

où R^{17} est choisi parmi le groupe constitué par un hydrogène, un mercapto, un alkyle en C_1-C_6 , un aryle et un aryl-alkyle en C_1-C_6 ;

où ledit aryle tel qu'on l'emploie dans la définition précédente est choisi parmi le groupe constitué par un phényle et un phényle substitué,

ledit phényle substitué ayant 1 à 3 substituants choisis chacun indépendamment parmi le groupe constitué par un halogéno, un alkyle en C_1-C_6 , un alcoxy en C_1-C_6 et un trifluorométhyle.

2. Un composé chimique choisi parmi le groupe constitué par la cis-1-[4-[2-(2,4-dichlorophényl)-2-(1H-1,2,4-triazol-1-ylméthyl)-1,3-dioxolan-4-ylméthoxy]-phényl]-4-[4-(1H-imidazol-1-yl)phényl]pipérazine et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques.

3. Un composé chimique choisi parmi le groupe constitué par la cis-1-[4-[2-(2,4-dichlorophényl)-2-(1H-imidazol-1-ylméthyl)-1,3-dioxolan-4-ylméthoxy]-phényl]-4-[4-(1H-1,2,4-triazol-1-yl)phényl]pipérazine et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques.

4. Un composé chimique choisi parmi le groupe constitué par la cis-4-[4-[4-[2-(2,4-dichlorophényl)-2-(1H-imidazol-1-ylméthyl)-1,3-dioxolan-4-ylméthoxy]phényl]-1-pipérazinyl]phényl]-2,4-dihydro-2,5-diméthyl-3H-1,2,4-triazol-3-one et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques.

5. Un composé chimique choisi parmi le groupe constitué par la cis-4-[4-[4-[2-(2,4-dichloro-



(67)

phényl)-2-(1H-1,2,4-triazol-1-ylméthyl)-1,3-dioxolan-4-ylméthoxy]phényl]-1-pipérazinyl]phényl]-2,4-dihydro-2,5-diméthyl-3H-1,2,4-triazol-3-one monohydratée et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques.

- 5 6. Un composé chimique choisi parmi le groupe constitué par la cis-1-[4-[2-(2,4-dichlorophényl)-2-(1H-1,2,4-triazol-1-ylméthyl)-1,3-dioxolan-4-ylméthoxy]phényl]-4-[4-(1H-tétrazol-1-yl)phényl]pipérazine et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques.

7. Un composé chimique choisi parmi le groupe constitué par la cis-1-[4-[2-(2,4-dichlorophényl)-2-(1H-1,2,4-triazol-1-ylméthyl)-1,3-dioxolan-4-ylméthoxy]phényl]-4-[4-[3-(méthylthio)-1H-1,2,4-triazol-1-yl]phényl]pipérazine et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques.


8. Un composé chimique choisi parmi le groupe constitué par la cis-4-[4-[4-[2-(2,4-dichlorophényl)-2-(1H-1,2,4-triazol-1-ylméthyl)-1,3-dioxolan-4-ylméthoxy]phényl]-1-pipérazinyl]phényl]-2-éthyl-2,4-dihydro-5-méthyl-3H-1,2,4-triazol-3-one et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques.

9. Un composé chimique choisi parmi le groupe constitué par la cis-4-[4-[4-[2-(2,4-dichlorophényl)-2-(1H-1,2,4-triazol-1-ylméthyl)-1,3-dioxolan-4-ylméthoxy]phényl]-1-pipérazinyl]phényl]-2,4-dihydro-5-méthyl-2-propyl-3H-1,2,4-triazol-3-one monohydratée et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques.

10. Un composé chimique choisi parmi le groupe constitué par la cis-4-[4-[4-[2-(2,4-dichlorophényl)-2-(1H-1,2,4-triazol-1-ylméthyl)-1,3-dioxolan-4-ylméthoxy]phényl]-1-pipérazinyl]phényl]-2-éthyl-2,4-dihydro-3H-1,2,4-triazol-3-one et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques.

11. Une composition pour lutter contre le développement d'un micro-organisme choisi parmi le groupe constitué par les champignons et les bactéries, comprenant une matière support inerte et comme ingrédient actif une quantité antifongique ou antibactérienne efficace d'un composé selon l'une quelconque des revendications 1 à 10.

12. Un composé chimique ayant pour formule:




et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques, où: Q est un élément choisi parmi le groupe constitué par CH et N;

- Ar est un élément choisi parmi le groupe constitué par phényle, thiényle, halogénothiényle et phényle substitué, ledit phényle substitué ayant 1 à 3 substituants choisis chacun indépendamment parmi le groupe constitué, par halogéno, alkyle inférieur, alcoxy inférieur et trifluorométhyle.

13. Composition pour lutter contre le développement d'un micro-organisme choisi parmi le groupe constitué par les champignons et les bactéries, comprenant une matière support inerte et comme ingrédient actif une quantité antifongique ou antibactérienne efficace d'un composé selon la revendication 12.

14. Un procédé pour préparer un composé chimique selon la revendication 1, caractérisé par a) la réaction d'un composé de formule:



- 60 avec un composé de formule




(II)



0006711


où D est



W est un reste d'ester réactif;


Y' est semblable à Y comme précédemment défini, mais est autre qu'un radical de formule (c) ou (g) où R⁸, et respectivement R¹⁷ sont un mercapto et autres qu'un radical de formule (d) ou (e) où R¹¹ ou R¹², et respectivement R¹³, sont un mercapto ou un hydroxy;

pour préparer un composé de formule




la réaction étant effectuée dans un solvant organique approprié inerte dans la réaction, à des températures élevées, et, si on le désire, d'abord la conversion du phénol substitué en un de ses sels métalliques et l'emploi ensuite dudit sel métallique dans la réaction avec (II); ou

b) la cyclisation d'un composé de formule




avec un composé de formule:



la réaction étant effectuée par agitation ensemble des composés réagissants en présence d'un solvant polaire approprié, en mélange avec un solvant organique miscible à l'eau approprié ou

c) la N-alkylation d'un composé de formule




avec un composé de formule



ladite N-alkylation étant effectuée par agitation ensemble des composés réagissants, en présence d'une base appropriée; ou

d) la cyclisation d'un composé de formule







0006711

où A est un groupe amino ou un dérivé approprié correspondant, avec un agent de cyclisation approprié et, si on le désire, introduction de substituants dans les composés hétérocycliques ainsi obtenus, la nature de A dans la formule (VIII) ainsi que la nature de l'agent de cyclisation que l'on utilise dans le stade de cyclisation dépendant de la signification de Y dans les composés désirés (I).


d)(i) les composés de formule (I) où Y représente le radical (a) où R¹, R², R³ et R⁴ ont la signification précédemment définie, dérivant d'une amine appropriée de formule




15 par cyclisation de ce dernier composé avec un composé de formule



ou un composé de formule




pour préparer un composé de formule




la réaction de (VIII-a) avec (IX-a) étant effectuée en agitant et portant à reflux ensemble les composés réagissants dans un solvant approprié, en présence d'une base appropriée;

d)(ii) les composés de formule (I) où Y représente la radical (b) où R⁵, R⁶ et R⁷ ont la signification précédemment définie dérivant d'une hydrazine appropriée de formule




par cyclisation de cette dernière avec une dione appropriée de formule



65




pour préparer un composé de formule



la réaction de (VIII-b) avec (X) étant effectuée selon le même mode opératoire que pour la préparation de (I-a) à partir de (VIII-a) et de (IX-a), et lorsque R⁵ est un hydrogène, le groupe carbonyle adjacent de (X) est de préférence acétalisé avant la réaction dudit (X) avec (VIII-b) pour obtenir un dérivé de pyrazole où R⁶ est situé de façon bien déterminée dans la position 5;


d)(iii) les composés de formule (I) où Y représente un radical (c) où R⁹ et R¹⁰ sont comme précédemment défini et où R⁸ représente un mercapto, étant préparés par cyclisation d'un isothiocyanate approprié de formule




avec un composé de formule




pour préparer un composé de formule



la réaction de (VIII-c) avec (XI) étant effectuée par agitation ensemble des composés réagissants dans un solvant organique approprié en présence d'une base appropriée, les composés de formule (I) où Y représente le radical (c) où R⁹ et R¹⁰ sont comme précédemment défini et où R⁸ représente un hydrogène, étant obtenus par désulfuration d'un composé de formule (I-c-1) pour préparer un composé de formule




les composés de formule (I) où Y représente le radical (c) où R⁹ et R¹⁰ sont comme précédemment décrit et où R⁸ est un alkylthio en C₁-C₆ ou un aryl-alkylthio en C₁-C₆, étant préparés en soumettant les composés correspondants de formule (I-c-1) à une S-alkylation standard avec un ester réactif approprié de formule R⁸W (XII) où R⁸ est un alkyle en C₁-C₆ ou un aryl-alkyle en C₁-C₆ et où W est comme précédemment défini, pour préparer un composé de formule






et, si on le désire, les composés de formule (I-c-3) peuvent être désulfurés pour fournir les composés de formule (I-c-2); ou


e) la préparation des composés de formule (I) où Y est le radical (d), où R¹¹ représente XH, X étant O ou S, et où R¹² est un hydrogène, un alkyle en C₁—C₆ ou un aryl-alkyle en C₁—C₆, ledit R¹² étant représenté par R¹²_a par cyclisation d'un composé de formule



avec



ou un de ses dérivés fonctionnels, le produit obtenu étant un composé de formule




30 ladite réaction étant effectuée de façon appropriée en agitant et chauffant ensemble les composés réagissants dans un solvant organique approprié; ou


e)(i) les composés de formule (I-d-1) peuvent sinon être préparés tout d'abord par acylation de (VIII-a-1) avec un anhydride approprié de formule



ou un halogénure alcooïque de formule




pour préparer un composé de formule



et, ensuite, cyclisation de ce dernier par agitation et chauffage de (XIV) dans un milieu alcalin alcoolique;

55 ou

e)(ii) préparation des composés de formule (I-d-1) par réaction d'un chlorhydrate d'hydrazine de formule (VIII-b) avec un composé de formule




dans la N,N-diéthyléthanamine, lavage du mélange réactionnel avec de l'eau, élimination du solvant par évaporation puis agitation et chauffage du résidu dans un mélange de dichlorométhane et d'éthanol en présence d'un alcali;


65 ou



e)(iii) préparation des composés de formule (I) où Y représente le radical (d) où R^{12} est R^{12}_a et où R^{11} est un hydrogène par désulfuration d'un composé correspondant de formule (I-d-1) où XH est SH, lesdits composés étant représentés par la formule




15 selon le même mode opératoire que pour la désulfuration de (I-c-1) pour préparer (I-c-2), le produit étant un composé de formule:




ou

e)(iv) la préparation de composés de formule (I) où Y représente le radical (d) où R^{12} est R^{12}_a et où R^{11} est un alkylthio en C_1-C_8 ou un aryl-alkylthio en C_1-C_8 , par S-alkylation d'un composé de formule (I-d-1-a) avec un ester réactif de formule $R^{11}_a W$, (XV-a), où W a la signification précédemment définie et où R^{11}_a représente un alkyle en C_1-C_8 ou un aryl-alkyle en C_1-C_8 , selon le même mode opératoire que pour la préparation de (I-c-3) à partir de (I-c-1) et (XII), le produit étant un composé de formule



45 et, si on le désire, selon le même mode de désulfuration que précédemment décrit, les composés de formule (I-d-3) peuvent être transformés en les composés de formule (I-d-2); ou

e)(v) la préparation de composés de formule (I) où Y représente le radical (d) où R^{12} est XH, X étant O ou S, et où R^{11} est un hydrogène, un alkyle en C_1-C_8 ou un aryl-alkyle en C_1-C_8 , ledit R^{11} étant représenté par R^{11}_b , par cyclisation d'un composé de formule




avec un composé de formule







ou un de ses dérivés fonctionnels, le produit étant un composé de formule




e)(vi) la préparation de composés de formule (I) où Y représente la radical (d) où R^{12} est un hydrogène et où R^{11} a la signification de R^{11}_b , par désulfuration d'un composé de formule



le produit étant un composé de formule




e)(vii) la préparation de composés de formule (I) où Y représente le radical (d) où R^{12} est un alkylthio en C_1-C_8 ou un aryl-alkylthio en C_1-C_8 et où R^{11} a la signification de R^{11}_b , par S-alkylation d'un composé de formule (I-d-4-a) avec un ester réactif de formule R^{12}_bW , (XV-b), où W est comme précédemment décrit et où R^{12}_b est un alkyle en C_1-C_8 ou un aryl-alkyle en C_1-C_8 , selon le mode opératoire précédemment décrit pour la préparation de (I-c-3) à partir de (I-c-1) et de (XII), le produit étant un composé de formule




et suivant le mode de désulfuration décrit ci-dessus, les composés de formule (I-d-6) peuvent à leur tour être transformés en les composés de formule (I-d-5), ou

f) la préparation de composés de formule (I) où Y représente un radical de formule (e) où R^{14} a la signification précédemment définie et où R^{13} représente un mercapto ou un hydroxy, ledit R^{13} étant représenté par XH, où X est O ou S, par cyclisation d'un composé de formule






avec un composé de formule



(XVI)


ou un de ses sels d'addition d'acides, le produit étant un composé de formule



(I-e-1)

ou

f)(i) la préparation de composés de formule (I) où Y représente le radical (e) où R^{14} est comme précédemment défini et où R^{13} représente un alkylthio en C_1-C_6 ou un aryl-alkylthio en C_1-C_6 , ledit R^{13} étant représenté par SR^{13}_a , où R^{13}_a est un alkyle en C_1-C_6 ou un aryl-alkyle en C_1-C_6 , par S-alkylation d'un composé de formule




(I-e-1-a)

avec un composé de formule

 R^{13}_aW


(XVII)

le produit étant un composé de formule



(I-e-3)


et, si on le désire, les composés de formule (I) où Y représente le radical (e) où R^{14} est comme précédemment défini et où R^{13} représente un hydrogène, peuvent être préparés par désulfuration d'un composé correspondant de formule (I-e-1-a) ou d'un composé de formule (I-e-3), selon des réactions de désulfuration standards comme précédemment décrit ici, le produit étant un composé de formule



(I-e-2)

ou


g) la préparation de composés de formule (I) où Y représente un radical (f) où R^{15} et R^{16} ont la signification précédemment définie, peuvent dériver d'un composé approprié de formule



(I-e-1-b)




par N-alkylation de ce dernier avec un ester réactif approprié de formule $R^{15}W$ (XVIII) où W et R^{15} ont les significations précédemment définies, le produit étant un composé de formule




10 ou h) la préparation de composés de formule (I) où Y représente le radical (g) où R^{17} est comme précédemment défini, mais est autre qu'un mercapto, ledit R^{17} étant représenté par R^{17}_a , par cyclisation d'un composé de formule (VIII-a) avec un azide et un composé de formule



dans un milieu acide approprié, le produit étant un composé de formule




25 ou h)(i) la préparation de composés de formule (I) où Y représente le radical (g) où R^{17} représente un mercapto, par cyclisation d'un isothiocyanate de formule (VIII-c) avec un azide approprié, dans un solvant organique approprié en présence d'un alcali, le produit étant un composé de formule



40 ou la réaction de cyclisation peut également être effectuée par agitation de (VIII-c) avec un azide en présence d'un sel d'ammonium quaternaire approprié, dans un système solvant approprié;

ou

h)(ii) la préparation de composés de formule (I-g) où R^{17} est un hydrogène, par désulfuration d'un composé de formule (I-g-2), le produit étant un composé de formule



55 et, si on le désire, la préparation des sels d'addition d'acides acceptables en pharmacie des produits des stades ci-dessus, et également, si on le désire, la préparation des formes isomères stéréochimiques des composés (I).

15. Un procédé pour préparer un composé chimique choisi parmi le groupe constitué par la cis-1 - [4 - [2 - (2,4 - dichlorophényl) - 2 - (1H - 1,2,4 - triazol - 1 - ylméthyl) - 1,3 - dioxolan - 4 - ylméthoxy]phényl] - 4 - [4 - (1H - imidazol - 1 - yl)phényl]pipérazine et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques, caractérisé par la réaction du

60 4 - [4 - [4 - (1H - imidazol - 1 - yl)phényl] - 1 - pipérazinyl]phénol avec le méthanesulfonate de cis-2 - (2,4 - dichlorophényl) - 2 - (1H - 1,2,4 - triazol - 1 - ylméthyl) - 1,3 - dioxolan - 4 - ylméthyle].

16. Un procédé pour préparer un composé chimique choisi parmi le groupe constitué par la cis-1 - [4 - [2 - (2,4 - dichlorophényl) - 2 - (1H - imidazol - 1 - ylméthyl) - 1,3 - dioxolan - 4 - ylméthoxy]phényl] - 4 - [4 - (1H - 1,2,4 - triazol - 1 - yl)phényl]pipérazine et ses sels d'addition d'acides



acceptables en pharmacie et leurs formes isomères stéréochimiques, caractérisé par la réaction du 4 - [4 - [4 - (1H - 1,2,4 - triazol - 1 - yl)phényl] - 1 - pipérazinyl]phénol avec le méthanesulfonate de cis - [2 - (2,4 - dichlorophényl) - 2 - (1H - imidazol - 1 - ylméthyl) - 1,3 - dioxolan - 4 - ylméthyle].

17. Un procédé pour préparer un composé chimique choisi parmi le groupe constitué par la cis - 4 - [4 - [4 - [4 - [2 - (2,4 - dichlorophényl) - 2 - (1H - imidazol - 1 - ylméthyl) - 1,3 - dioxolan - 4 - ylméthoxy]phényl] - 1 - pipérazinyl]phényl] - 2,4 - dihydro - 2,5 - diméthyl - 3H - 1,2,4 - triazol - 3 - one et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques, caractérisé par la réaction de la 2,4 - dihydro - 4 - [4 - [4 - (4 - hydroxyphényl) - 1 - pipérazinyl]phényl] - 2,5 - diméthyl - 3H - 1,2,4 - triazol - 3 - one avec le méthanesulfonate de cis - [2 - (2,4 - dichlorophényl) - 2 - (1H - imidazol - 1 - ylméthyl) - 1,3 - dioxolan - 4 - ylméthyle].


18. Un procédé pour préparer un composé chimique choisi parmi le groupe constitué par la cis - 4 - [4 - [4 - [4 - [2 - (2,4 - dichlorophényl) - 2 - (1H - 1,2,4 - triazol - 1 - ylméthyl) - 1,3 - dioxolan - 4 - ylméthoxy]phényl] - 1 - pipérazinyl]phényl] - 2,4 - dihydro - 2,5 - diméthyl - 3H - 1,2,4 - triazol - 3 - one monohydratée et ses sels d'addition d'acides acceptables en pharmacie et leurs formes isomères stéréochimiques, caractérisé par la réaction de la 2,4 - dihydro - 4 - [4 - [4 - (4 - hydroxyphényl) - 1 - pipérazinyl]phényl] - 2,5 - diméthyl - 3H - 1,2,4 - triazol - 3 - one avec le méthanesulfonate de cis - [2 - (2,4 - dichlorophényl) - 2 - (1H - 1,2,4 - triazol - 1 - ylméthyl) - 1,3 - dioxolan - 4 - ylméthyle].

19. Un procédé pour préparer un composé de formule cis - 1 - [4 - [2 - (2,4 - dichlorophényl) - 2 - (1H - 1,2,4 - triazol - 1 - ylméthyl) - 1,3 - dioxolan - 4 - ylméthoxy]phényl] - 4 - [4 - (5 - méthyl - 1H - 1,2,4 - triazol - 1 - yl)phényl]pipérazine, caractérisé par la réaction du 4 - [4 - [4 - (5 - méthyl - 1H - 1,2,4 - triazol - 1 - yl)phényl] - 1 - pipérazinyl]phénol avec le méthanesulfonate de cis - [2 - (2,4 - dichlorophényl) - 2 - (1H - 1,2,4 - triazol - 1 - ylméthyl) - 1,3 - dioxolan - 4 - ylméthyle].

20. Un procédé pour préparer un composé chimique selon la revendication 12, caractérisé par la réaction d'un composé (II) de formule $D-CH_2-W$ (II) où D est



et W est un reste d'ester réactif, avec un composé de formule



dans un solvant organique approprié inerte dans la réaction, à des températures élevées ou, si on le désire, d'abord la conversion du phénol substitué en un de ses sels métalliques puis l'emploi dudit sel métallique dans la réaction avec (II).

21. Un composé selon l'une quelconque des revendications 1 à 10 ou la revendication 12, ou une composition selon la revendication 11 ou la revendication 13, pour l'emploi dans la lutte contre le développement d'un champignon ou d'une bactérie.

22. Un procédé pour préparer une composition pharmaceutique comprenant le mélange d'une quantité efficace d'un composé revendiqué dans l'une quelconque des revendications 1 à 10 ou 12 avec une matière support inerte.